{"id":"epcoritamab","rwe":[{"pmid":"41896935","year":"2026","title":"Cytokine release syndrome-compatible fever after initiation of local radiotherapy during late-phase epcoritamab therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report.","finding":"","journal":"Journal of pharmaceutical health care and sciences","studyType":"Clinical Study"},{"pmid":"41881714","year":"2026","title":"Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6.","finding":"","journal":"Clinical lymphoma, myeloma & leukemia","studyType":"Clinical Study"},{"pmid":"41867647","year":"2026","title":"Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report.","finding":"","journal":"Case reports in oncology","studyType":"Clinical Study"},{"pmid":"41835636","year":"2026","title":"Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41813134","year":"2026","title":"Diffuse Large B-cell Lymphoma Complicated by Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity on Day 355 of Epcoritamab Therapy: A Case Report.","finding":"","journal":"Journal of clinical and experimental hematopathology : JCEH","studyType":"Clinical Study"}],"_fda":{"id":"13fee518-576f-45f0-885a-b6b537128dde","set_id":"d7836711-b677-412d-bf2d-0f7c8444103a","openfda":{"nui":["N0000194063","N0000175078","N0000175617","N0000175618","N0000009267","N0000182136"],"unii":["D6OMY2L0WA"],"route":["SUBCUTANEOUS"],"rxcui":["2637399","2637405","2637408","2637411"],"spl_id":["13fee518-576f-45f0-885a-b6b537128dde"],"brand_name":["EPKINLY"],"spl_set_id":["d7836711-b677-412d-bf2d-0f7c8444103a"],"package_ndc":["82705-010-01","82705-002-01"],"product_ndc":["82705-002","82705-010"],"generic_name":["EPCORITAMAB-BYSP"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Increased Cytokine Activity [PE]"],"substance_name":["EPCORITAMAB"],"pharm_class_epc":["Bispecific CD20-directed CD3 T Cell Engager [EPC]"],"pharm_class_moa":["CD20-directed Antibody Interactions [MoA]","CD3-directed Antibody Interactions [MoA]","CD3 Receptor Agonists [MoA]","Cytochrome P450 Inhibitors [MoA]"],"manufacturer_name":["Genmab US, Inc."],"application_number":["BLA761324"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary Based on the mechanism of action, EPKINLY may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of EPKINLY in pregnant women to evaluate for a drug-associated risk. No animal reproductive or developmental toxicity studies have been conducted with epcoritamab-bysp. Epcoritamab-bysp causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD20 on B-cells and the finding of B-cell depletion in non-pregnant animals, epcoritamab-bysp can cause B-cell lymphocytopenia in infants exposed to epcoritamab-bysp in-utero. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, EPKINLY has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."],"description":["11 DESCRIPTION Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager; it is a humanized bispecific IgG1 antibody. Epcoritamab-bysp is manufactured in Chinese hamster ovary (CHO) cells using recombinant DNA technology and has an approximate molecular weight of 149 kDa. EPKINLY (epcoritamab-bysp) injection for subcutaneous use is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, free of visible particles. Each single-dose 4 mg/0.8 mL vial contains epcoritamab-bysp (4 mg), acetic acid (0.19 mg), polysorbate 80 (0.32 mg), sodium acetate (1.7 mg), sorbitol (21.9 mg) and Water for Injection, USP. The pH is 5.5. Each single-dose 48 mg/0.8 mL vial contains epcoritamab-bysp (48 mg), acetic acid (0.19 mg), polysorbate 80 (0.32 mg), sodium acetate (1.7 mg), sorbitol (21.9 mg) and Water for Injection, USP. The pH is 5.5."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied EPKINLY (epcoritamab-bysp) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, free of visible particles, supplied in glass vials as follows: Carton contents NDC number One 4 mg/0.8 mL single-dose vial NDC 82705-002-01 One 48 mg/0.8 mL single-dose vial NDC 82705-010-01 The vial stopper is not made with natural rubber latex. Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light. Do not freeze. Do not shake."],"spl_medguide":["This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: Mar 2026 MEDICATION GUIDE EPKINLY ® (ep-KIN-lee) (epcoritamab-bysp) injection, for subcutaneous use What is the most important information I should know about EPKINLY? EPKINLY can cause serious side effects, including: Cytokine Release Syndrome (CRS) . CRS is common during treatment with EPKINLY and can also be serious or lead to death. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including: fever of 100.4°F (38°C) or higher dizziness or light-headedness trouble breathing chills fast heartbeat feeling anxious headache confusion shaking (tremors) problems with balance and movement, such as trouble walking Due to the risk of CRS, you will receive EPKINLY on a \"step-up dosing schedule\". The step-up dosing schedule is when you receive 2 or 3 smaller \"step-up\" doses of EPKINLY during your first cycle of treatment (Cycle 1). You will receive your first full dose of EPKINLY a week after your last step-up dose (this will be Day 15 or Day 22 of Cycle 1). If your dose of EPKINLY is delayed for any reason, you may need to repeat the \"step-up dosing schedule\". Before each dose in Cycle 1, you will receive medicines to help reduce your risk of CRS. You will also receive medicine for 3 days after each dose in Cycle 1. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles. See \" How will I receive EPKINLY? \" for more information about how you will receive EPKINLY. Neurologic problems. EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including: trouble speaking or writing confusion and disorientation drowsiness tiredness or lack of energy muscle weakness shaking (tremors) seizures memory loss Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe. People with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems. People with follicular lymphoma (FL) may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems. See \" What are the possible side effects of EPKINLY? \" for more information about side effects. What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with: certain types of DLBCL or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory),after 2 or more treatments. follicular lymphoma that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab. follicular lymphoma that has come back or that did not respond after 2 or more treatments. It is not known if EPKINLY is safe and effective in children. Before receiving EPKINLY, tell your healthcare provider about all of your medical conditions, including if you: have an infection. are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY. You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive EPKINLY? EPKINLY will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in the lower part of your stomach-area (abdomen) or thigh. Your EPKINLY treatment schedule is divided into cycles that are usually 28 days (4 weeks) long. Your healthcare provider will decide how many treatment cycles you will receive and how often you will receive EPKINLY in each cycle. See \" What is the most important information I should know about EPKINLY? \" for more information about how you will receive EPKINLY. What should I avoid while receiving EPKINLY? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. See \" What is the most important information I should know about EPKINLY? \" for more information about signs and symptoms of CRS and neurologic problems. What are the possible side effects of EPKINLY? EPKINLY can cause serious side effects, including: See \" What is the most important information I should know about EPKINLY? \" Infections. EPKINLY can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment with EPKINLY. Your healthcare provider should prescribe medicines before you start treatment to help prevent infection and treat you as needed if you develop an infection during treatment with EPKINLY. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with EPKINLY, including: fever of 100.4°F (38°C) or higher cough chest pain tiredness shortness of breath painful rash sore throat pain during urination feeling weak or generally unwell confusion Low blood cell counts. EPKINLY can cause low blood cell counts which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment with EPKINLY. EPKINLY may cause the following low blood cell counts: low white blood cell counts (neutropenia and lymphopenia). Low white blood cells can increase your risk for infection. low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath. low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include: CRS injection site reactions tiredness muscle and bone pain fever diarrhea COVID-19 rash stomach area (abdominal pain) The most common severe abnormal laboratory test results with EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include: decreased white blood cells, decreased red blood cells, and decreased platelets. The most common side effects of EPKINLY when used together with lenalidomide and rituximab in follicular lymphoma include: rash upper respiratory tract infections tiredness injection site reactions constipation diarrhea CRS pneumonia COVID-19 fever The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab in follicular lymphoma include: decreased white blood cells and decreased platelets. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about safe and effective use of EPKINLY. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about EPKINLY that is written for health professionals. What are the ingredients in EPKINLY? Active ingredient: epcoritamab-bysp Inactive ingredients: acetic acid, polysorbate 80, sodium acetate, sorbitol and Water for Injection. Manufactured by: Genmab US, Inc., Plainsboro, NJ 08536 U.S. License Number: 2293 Marketed by: Genmab US, Inc., Plainsboro, NJ 08536 and AbbVie Inc., North Chicago, IL 60064 EPKINLY is a registered trademark owned by Genmab A/S ©2026 Genmab A/S For more information, go to www.EPKINLY.com or call 1-855-4GENMAB (1-855-443-6622)"],"boxed_warning":["WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.1) ] . Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE SYNDROME and IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME See full prescribing information for complete boxed warning. Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.1 ) Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.2 )"],"geriatric_use":["8.5 Geriatric Use LBCL In patients with relapsed or refractory LBCL who received EPKINLY in EPCORE NHL-1, 77 (49%) were 65 years of age and older, and 29 (19%) were 75 years of age or older. No clinically meaningful differences in safety or efficacy were observed between patients with relapsed or refractory LBCL who were 65 years of age and older compared with younger adult patients. FL In patients with relapsed or refractory FL who received EPKINLY in combination with lenalidomide and rituximab in EPCORE FL-1, 88 (36%) were 65 years of age or older and 20 (8%) were 75 years of age or older. No clinically meaningful differences in safety or efficacy were observed between patients who were 65 years of age and older compared with younger patients. In patients with relapsed or refractory FL who received EPKINLY in EPCORE NHL-1, 66 (52%) were 65 years of age or older, and 16 (13%) were 75 years of age and older. In patients with relapsed or refractory FL, there was a higher rate of fatal adverse reactions, primarily infections, including COVID-19, in patients older than 65 years of age compared to younger adult patients. No overall difference in efficacy was observed in patients with relapsed or refractory FL who were 65 years of age and older compared with younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of EPKINLY in pediatric patients have not been established."],"effective_time":"20260401","clinical_studies":["14 CLINICAL STUDIES 14.1 DLBCL and High-grade B-cell Lymphoma The efficacy of EPKINLY was evaluated in EPCORE NHL-1 (Study GCT3013-01; NCT03625037), an open-label, multi-cohort, multicenter, single-arm trial in 157 patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The study excluded patients with CNS involvement of lymphoma, allogeneic HSCT or solid organ transplant, ongoing active infection, and any patients with known impaired T-cell immunity. Patients received EPKINLY monotherapy at the recommended 2-step up dosage schedule: Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22 Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22 Cycles 4-9: EPKINLY 48 mg on Days 1 and 15 Cycles 10 and beyond: EPKINLY 48 mg on Day 1 Patients continued to receive EPKINLY until disease progression or unacceptable toxicity. In the setting of a suspected tumor flare reaction, continued treatment was permitted. The efficacy population includes 148 patients with DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma. Of the 148 patients, the median age was 65 years (range: 22 to 83), 62% were male, 97% had an ECOG performance status of 0 or 1, and 3% had an ECOG performance status of 2. Race was reported in 125 (84%) patients; of these patients, 61% were White, 20% were Asian, and 0.7% were Native Hawaiian or Other Pacific Islander. There were no Black or African American or Hispanic or Latino patients treated in the clinical trial as reported. The diagnosis was DLBCL NOS in 86%, including 27% with DLBCL transformed from indolent lymphoma, and high-grade B-cell lymphoma in 14%. The median number of prior therapies was 3 (range: 2 to 11), with 30% receiving 2 prior therapies, 30% receiving 3 prior therapies, and 40% receiving 4 or more prior therapies. Eighteen percent had prior autologous HSCT, and 39% had prior chimeric antigen receptor (CAR) T-cell therapy. Eighty-two percent of patients had disease refractory to last therapy and 29% of patients were refractory to CAR T-cell therapy. Efficacy was established based on overall response rate (ORR) and duration of response as assessed by an Independent Review Committee (IRC) using Lugano 2014 criteria. The efficacy results are summarized in Table 18. Table 18: Efficacy Results in EPCORE NHL-1 in Patients with DLBCL and High-grade B-cell Lymphoma Endpoint Determined by Lugano criteria (2014) as assessed by independent review committee (IRC). EPKINLY (N=148) ORR = overall response rate; CI = confidence interval; CR = complete response; PR = partial response; DOR = duration of response; NR = not reached. ORR Early response assessments were evaluated in the context of potential flare reactions. Of 90 patients who achieved an objective response, 9 patients had early flare reactions identified with objective response demonstrated on subsequent imaging per Lugano criteria. , n (%) 90 (61) (95% CI) (52.5, 68.7) CR, n (%) 56 (38) (95% CI) (30.0, 46.2) PR, n (%) 34 (23) (95% CI) (16.5, 30.6) DOR Median (95% CI), months 15.6 (9.7, NR) 9-month estimate Kaplan-Meier estimate. (95% CI), % 63 (51.5, 72.4) The median time to response was 1.4 months (range: 1 to 8.4 months). Among responders, the median follow-up for DOR was 9.8 months (range: 0.0 to 17.3 months). 14.2 Follicular Lymphoma EPKINLY in Combination with Lenalidomide and Rituximab for FL The efficacy of EPKINLY in combination with lenalidomide and rituximab was evaluated in EPCORE FL-1 (Study M20-638; NCT05409066), an open-label, randomized, multicenter, global trial in patients with relapsed or refractory FL after at least one line of systemic therapy. Patients were randomized to receive EPKINLY in combination with lenalidomide and rituximab, or lenalidomide and rituximab alone. The study excluded patients with known CNS involvement by lymphoma, prior allograft, and known active infection. Patients received EPKINLY via subcutaneous injection in 28-day cycles for a total of 12 cycles or until disease progression or unacceptable toxicity, whichever occurred first. The recommended EPKINLY dosage schedule was: Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15 and 48 mg on Day 22 Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22 Cycles 4-12: EPKINLY 48 mg on Day 1 In both treatment arms, lenalidomide was given orally at a dose of 20 mg once daily from Days 1 to 21 for 12 cycles and Rituximab was administered intravenously at a dose of 375 mg/m 2 on Days 1, 8, 15, and 22 of Cycle 1, followed by administration on Day 1 of Cycles 2 to 5. Of all patients randomized, the median age was 61 years (range: 24 to 89 years), with 40% being age 65 or older; 57% were male; 72% were White, 24% Asian, and 2% were Black; and 98% had an ECOG performance status of 0 or 1. The median number of prior lines of systemic therapy was 1 (range: 1 to 7) with 24% receiving 2 prior lines and 17% receiving 3 or more prior lines of therapy. Forty-one percent had progressive disease within 24 months of first systemic therapy. Efficacy was established based on progression free survival (PFS) and overall response rate (ORR) as assessed by Independent Review Committee (IRC) using Lugano 2014 criteria. The efficacy results, based on a prespecified interim analysis, are summarized in Table 19 and the Kaplan-Meier plot of PFS presented in Figure 1. The results are based on a median duration of follow-up of 10.4 months in the intention-to-treat population. Table 19: Efficacy Results in EPCORE FL-1 in Patients with FL Outcome per IRC EPKINLY + Lenalidomide and Rituximab (N=243) Lenalidomide and Rituximab (N=245) PFS = progression free survival; CI = confidence interval; NR = not reached; ORR = overall response rate; CR = complete response. PFS Number of events, n (%) 23 (9) 75 (31) Progressive disease 19 (83) 63 (84) Death 4 (17) 12 (16) Median (95% CI), months NR (21.9, NR) 11.2 (10.5, NR) Hazard ratio Cox proportional hazards hazard ratio stratified by disease history and region. (95% CI) 0.21 (0.13, 0.33) P-value Log-rank p-value (one sided) stratified by disease history and region. < 0.0001 ORR, n (%) 216 (89) 181 (74) (95% CI) (84, 93) (68, 79) P-value P-value is based on a prespecified analysis of the first 232 patients randomized. , P-value (one sided) is from a Cochran-Mantel-Haenszel test stratified by disease history and region. < 0.0001 CR, n (%) 181 (74) 106 (43) (95% CI) (69, 80) (37, 50) P-value < 0.0001 Figure 1: Kaplan-Meier Plot of PFS per IRC After a median duration of follow-up of 14.8 months overall, the median overall survival had not been reached in either arm with a total of 35 deaths: 10 (4%) deaths in the EPKINLY arm and 25 (10%) deaths in the lenalidomide and rituximab arm. EPKINLY as Monotherapy for FL The efficacy of EPKINLY as monotherapy was evaluated in EPCORE NHL-1 (Study GCT3013-01; NCT03625037), an open-label, multi-cohort, multicenter, single-arm trial that included patients with relapsed or refractory follicular lymphoma (FL) after at least 2 lines of systemic therapy. The study excluded patients with CNS involvement of lymphoma, allogeneic HSCT or solid organ transplant, ongoing active infection, any patients with known impaired T-cell immunity, creatinine clearance < 45 mL/min, alanine aminotransferase > 3 times the upper limit of normal, and a cardiac ejection fraction < 45%. Patients received EPKINLY monotherapy following a 2-step up dosage schedule: Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22 Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22 Cycles 4-9: EPKINLY 48 mg on Days 1 and 15 Cycles 10 and beyond: EPKINLY 48 mg on Day 1 Patients continued to receive EPKINLY until disease progression or unacceptable toxicity. Among the 127 patients with FL, the median age was 65 years (range: 39 to 84), 52% were 65 years of age or older, and 62% were male. Race was reported in 85 (67%) patients; of these patients, 89% were White, and 8% were Asian. A total of 85% had stage III-IV disease, 25% had bulky disease, 95% had an ECOG performance status of 0 or 1, and 6% had an ECOG performance status of 2. The median number of prior therapies was 3 (range: 2 to 9), with 36% receiving 2 prior lines of systemic therapy, 32% receiving 3 prior therapies, and 32% receiving 4 or more prior therapies. Seventy-nine percent of patients were refractory to prior anti-CD20 monoclonal antibody therapy, 70% were refractory to both anti-CD20 monoclonal antibody and alkylator therapy, 21% had prior rituximab plus lenalidomide therapy, 19% received prior autologous HSCT, and 5% received prior chimeric antigen receptor (CAR) T-cell therapy. Fifty-two percent of patients had progression of disease within 24 months of first systemic therapy. Efficacy was established based on overall response rate (ORR) determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC) and duration of response. The median follow-up for DOR was 14.8 months. The efficacy results are summarized in Table 20. Table 20: Efficacy Results in EPCORE NHL-1 in Patients with FL Endpoint Determined by Lugano criteria (2014) as assessed by independent review committee (IRC). EPKINLY (N=127) ORR = overall response rate; CI = confidence interval; CR = complete response; PR = partial response; DOR = duration of response; NR = not reached. ORR, n (%) 104 (82) (95% CI) (74.1, 88.2) CR, n (%) 76 (60) (95% CI) (50.8, 68.4) PR, n (%) 28 (22) (95% CI) (15.2, 30.3) DOR Median (95% CI), months NR (13.7, NR) 12-month estimate Kaplan-Meier estimate. % (95% CI) 68.4 (57.6, 77.0) The median time to first response was 1.4 months (range: 1 to 3 months). In a separate dose optimization cohort in EPCORE NHL-1, 86 patients received the recommended 3-step up dosage schedule in Cycle 1 [see Adverse Reactions (6.1) ] . The efficacy results in this cohort were comparable to the primary efficacy population. Figure 1"],"pharmacodynamics":["12.2 Pharmacodynamics Circulating B-Cell Count Circulating B-cells decreased to undetectable levels (< 10 cells/microliter) after administration of the approved recommended dosage of EPKINLY in patients who had detectable B-cells at treatment initiation by Cycle 1 Day 15 and the depletion was sustained while patients remained on treatment. Cytokine Concentrations Plasma concentrations of cytokines (IL-2, IL-6, IL-10, TNF-α, and IFN-γ) were measured. Transient elevation of circulating cytokines was observed at dose levels of 0.04 mg and above. After administration of the approved recommended dosages of EPKINLY, cytokine levels increased within 24 hours after the first dose on Cycle 1 Day 1, generally reached maximum levels after the first 48 mg dose, and returned to baseline prior to the second 48 mg full dose."],"pharmacokinetics":["12.3 Pharmacokinetics Pharmacokinetic (PK) parameters were evaluated at the approved recommended dosage (48 mg) and are presented as geometric mean (CV%) unless otherwise specified. Epcoritamab-bysp area under the concentration-time curve (AUC) increased more than proportionally over a full dosage range from 1.5 to 60 mg (0.03125 to 1.25 times the approved recommended dosage). Epcoritamab-bysp maximum concentration (10.2 mcg/mL [43.2%]) is achieved after the first dose of the Q2W regimen (i.e., the first dose of Cycle 4). No clinically significant differences in pharmacokinetic parameters were observed between patients with relapsed or refractory LBCL and patients with relapsed or refractory FL. PK exposures are summarized for the recommended dosage of EPKINLY in Table 17. Table 17: Exposure Parameters of Epcoritamab-bysp in Subjects with Relapsed or Refractory LBCL or FL Following Recommended Dosage C avg (mcg/mL) Values are geometric mean with geometric CV%. C max (mcg/mL) C trough (mcg/mL) First full 48 mg dose First full 48 mg dose is on the first day of Week 3 in subjects with relapsed or refractory LBCL and on the first day of Week 4 in subjects with relapsed or refractory FL. 1.3 (113.3%) 1.7 (106.7%) 1.4 (100.9%) End of weekly dosing (end of Cycle 3) 9.1 (45.9%) 9.9 (43.4%) 7.8 (52.4%) End of every 2-week dosing (end of Cycle 9) 5.3 (57%) 6.7 (49.4%) 3.6 (81.5%) Steady state Steady state values are approximated at Cycle 15 (Week 60). with every 4-week dosing 2.4 (73.3%) 4.2 (59.8%) 1.1 (134.1%) Absorption The median (range) T max of epcoritamab-bysp after the first full dose and end of the weekly dosing regimen (end of Cycle 3) treatment doses were 4 (0.3 to 7) days and 2.3 (0.3 to 3.2) days, respectively. Distribution The apparent total volume of distribution is 25.6 L (82%). Elimination The half-life of full dose epcoritamab-bysp (48 mg) was approximately 22 days (58%) at the end of Cycle 3, with apparent total clearance of approximately 0.53 L/day (40%) after the end of Cycle 3. Metabolism Epcoritamab-bysp is expected to be metabolized into small peptides by catabolic pathways. Specific Populations No clinically significant differences in the PK of epcoritamab-bysp were observed based on age (20 to 89 years), sex, race (White or Asian), mild to moderate renal impairment (creatinine clearance [CLcr] 30 to < 90 mL/min as estimated by Cockcroft-Gault formula), and mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin 1 to 1.5 times ULN and any AST) after accounting for differences in bodyweight. The effects of severe renal impairment (CLcr 15 to < 30 mL/min), end-stage renal disease (CLcr < 15 mL/min), or moderate to severe hepatic impairment (total bilirubin > 1.5 times ULN and any AST) on the PK of epcoritamab-bysp are unknown. Body Weight In patients who received the recommended dosage of EPKINLY, geometric mean average concentration following the first full 48 mg dose was 31% lower in the higher body weight (BW) group (85 to 172 kg) and 13% higher in the lower BW group (39 to 65 kg) compared to patients with BW of 65 to less than 85 kg. Drug Interaction Studies No clinical studies evaluating the drug interaction potential of epcoritamab-bysp have been conducted."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Cytokine Release Syndrome [see Warnings and Precautions (5.1) ]. Immune Effector Cell-Associated Neurotoxicity Syndrome [see Warnings and Precautions (5.2) ]. Infections [see Warnings and Precautions (5.3) ]. Cytopenias [see Warnings and Precautions (5.4) ]. EPKINLY as monotherapy for LBCL or FL: The most common (≥ 20%) adverse reactions are CRS, injection site reactions, fatigue, musculoskeletal pain, fever, diarrhea, COVID-19, rash and abdominal pain. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) are decreases in lymphocyte count, neutrophil count, hemoglobin, and platelets. ( 6.1 ) EPKINLY in combination with lenalidomide and rituximab for FL: The most common (≥ 20%) adverse reactions are rash, upper respiratory tract infections, fatigue, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) are decreased neutrophil count, lymphocyte count, and platelets. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Relapsed or Refractory Large B-cell Lymphoma (LBCL) EPCORE NHL-1 The safety of EPKINLY was evaluated in EPCORE NHL-1, a single-arm study of patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from indolent lymphoma, high grade B-cell lymphoma, and other B-cell lymphomas [see Clinical Studies (14.1) ] . A total of 157 patients with LBCL received EPKINLY via subcutaneous injection until disease progression or unacceptable toxicities according to the following 28-day cycle schedule: Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22 Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22 Cycles 4-9: EPKINLY 48 mg on Days 1 and 15 Cycles 10 and beyond: EPKINLY 48 mg on Day 1 Of the 157 patients treated, the median age was 64 years (range: 20 to 83), 60% were male, and 97% had an ECOG performance status of 0 or 1. Race was reported in 133 (85%) patients; of these patients, 61% were White, 19% were Asian, and 0.6% were Native Hawaiian or Other Pacific Islander. There were no Black or African American or Hispanic or Latino patients treated in the clinical trial as reported. The median number of prior therapies was 3 (range: 2 to 11). The study excluded patients with CNS involvement of lymphoma, allogeneic HSCT or solid organ transplant, an ongoing active infection, and any patients with known impaired T-cell immunity. The median duration of exposure for patients receiving EPKINLY was 5 cycles (range: 1 to 20 cycles). Serious adverse reactions occurred in 54% of patients who received EPKINLY. Serious adverse reactions in ≥ 2% of patients included CRS, infections (including sepsis, COVID-19, pneumonia, and upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, and ICANS. Fatal adverse reactions occurred in 3.8% of patients who received EPKINLY, including COVID-19 (1.3%), hepatotoxicity (0.6%), ICANS (0.6%), myocardial infarction (0.6%), and pulmonary embolism (0.6%). Permanent discontinuation of EPKINLY due to an adverse reaction occurred in 3.8% of patients. Adverse reactions which resulted in permanent discontinuation of EPKINLY included COVID-19, CRS, ICANS, pleural effusion, and fatigue. Dosage interruptions of EPKINLY due to an adverse reaction occurred in 34% of patients who received EPKINLY. Adverse reactions which required dosage interruption in ≥ 3% of patients included CRS, neutropenia, sepsis, and thrombocytopenia. The most common (≥ 20%) adverse reactions were CRS, fatigue, musculoskeletal pain, injection site reactions, pyrexia, abdominal pain, nausea, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, decreased hemoglobin, and decreased platelets. Table 11 summarizes the adverse reactions in EPCORE NHL-1. Table 11: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory LBCL Who Received EPKINLY in EPCORE NHL-1 EPKINLY (N=157) Adverse Reaction Adverse reactions were graded based on CTCAE Version 5.0 All Grades (%) Grade 3 or 4 (%) Immune system disorders Cytokine release syndrome CRS was graded using ASTCT consensus criteria (Lee et al., 2019). 51 2.5 Only grade 3 adverse reactions occurred. General disorders and administration site conditions Fatigue Fatigue includes asthenia, fatigue, lethargy. 29 2.5 Injection site reactions Injection site reaction includes injection site erythema, injection site hypertrophy, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, injection site urticaria. 27 0 Pyrexia 24 0 Edema Edema includes edema, edema peripheral, face edema, generalized edema, peripheral swelling. 14 1.9 Musculoskeletal and connective tissue disorders Musculoskeletal pain Musculoskeletal pain includes back pain, bone pain, flank pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain, pain in extremity, spinal pain. 28 1.3 Gastrointestinal disorders Abdominal pain Abdominal pain includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness. 23 1.9 Diarrhea 20 0 Nausea 20 1.3 Vomiting 12 0.6 Skin and subcutaneous disorders Rash Rash includes dermatitis bullous, erythema, palmar erythema, penile erythema, rash, rash erythematous, rash maculo-papular, rash pustular, recall phenomenon, seborrheic dermatitis, skin exfoliation. 15 0.6 Nervous system disorder Headache 13 0.6 Metabolism and nutrition disorders Decreased appetite 12 0.6 Cardiac disorders Cardiac arrhythmias Cardiac arrhythmias includes bradycardia, sinus bradycardia, sinus tachycardia, supraventricular extrasystoles, supraventricular tachycardia, tachycardia. 10 0.6 Clinically relevant adverse reactions in < 10% of patients who received EPKINLY included ICANS, sepsis, pleural effusion, COVID-19, pneumonia (including pneumonia and COVID-19 pneumonia), tumor flare, febrile neutropenia, upper respiratory tract infections, and tumor lysis syndrome. Table 12 summarizes laboratory abnormalities in EPCORE NHL-1. Table 12: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Relapsed or Refractory LBCL Who Received EPKINLY in EPCORE NHL-1 Laboratory Abnormality Laboratory abnormalities were graded based on CTCAE Version 5.0 EPKINLY The denominator used to calculate the rate varied from 146 to 153 based on the number of patients with a baseline value and at least one post-treatment value. All Grades (%) Grade 3 or 4 (%) Hematology Lymphocyte count decreased 87 77 Hemoglobin decreased 62 12 White blood cells decreased 53 22 Neutrophils decreased 50 32 Platelets decreased 48 12 Chemistry Sodium decreased 56 2.6 Phosphate decreased CTCAE Version 5.0 does not include numeric thresholds for grading of hypophosphatemia; all grades represent patients with lab value < Lower Limit of Normal (LLN). 56 N/A Aspartate aminotransferase increased 48 4.6 Alanine aminotransferase increased 45 5.3 Potassium decreased 34 5.3 Magnesium decreased 31 0 Creatinine increased 24 3.3 Potassium increased 21 1.3 Relapsed or Refractory Follicular Lymphoma (FL) EPCORE FL-1 The safety of EPKINLY in combination with lenalidomide and rituximab was evaluated in EPCORE FL-1, an open-label, randomized, multicenter trial that included patients with relapsed or refractory FL after at least one line of systemic therapy [see Clinical Studies (14.2) ] . The study excluded patients with transformed lymphoma, absolute neutrophil count < 1.0 × 10 9 /L, platelet count < 70 × 10 9 /L (or < 50 × 10 9 /L if bone marrow infiltration by lymphoma or splenomegaly), known active infection, creatinine clearance < 50 mL/min, alanine or aspartate transaminase > 3 times the upper limit of normal, and clinically significant cardiovascular disease. Patients were randomized to receive EPKINLY in combination with lenalidomide and rituximab (N=243) or lenalidomide and rituximab alone (N=238). Patients received EPKINLY via subcutaneous injection in 28-day cycles for a total of 12 cycles or until disease progression or unacceptable toxicity, whichever occurred first. Of the 243 patients who received EPKINLY, 131 received the recommended 3 step-up dosage schedule. The recommended EPKINLY dosage schedule was: Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15, and 48 mg on Day 22 Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22 Cycles 4-12: EPKINLY 48 mg on Day 1 In both treatment arms, lenalidomide was given orally at a dose of 20 mg once daily from Days 1 to 21 for 12 cycles. Rituximab was administered intravenously at a dose of 375 mg/m 2 on Days 1, 8, 15, and 22 of Cycle 1, followed by administration on Day 1 of Cycles 2 to 5. Safety results are based on all 243 patients who received EPKINLY, with the exception of data for CRS and ICANS which are based on patients who received EPKINLY at the recommended dosage schedule. The median duration of exposure in this arm was 10 cycles for EPKINLY and 9 cycles for lenalidomide. Serious adverse reactions occurred in 51% of these patients, including serious infections in 28% of patients and serious CRS in 12% of patients. Fatal adverse reactions within 60 days of last treatment occurred in 0.8% of patients. Adverse reactions led to permanent discontinuation of EPKINLY in 6% of patients and dose interruption in 75% of patients, with infection as a leading cause. Adverse reactions leading to interruption of EPKINLY in ≥ 5% of patients included respiratory tract infections, CRS, and rash. In the EPKINLY arm, adverse reactions led to lenalidomide dose interruption in 72%, dose reduction in 22%, and permanent discontinuation in 15%. The most common (≥ 20%) adverse reactions in the EPKINLY arm were rash, upper respiratory tract infections, fatigue, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreases in neutrophil count, lymphocyte count, and platelets. Table 13 summarizes select adverse reactions in EPCORE FL-1. Table 13: Adverse Reactions (≥ 10% All Grade and ≥ 5% Higher) in Patients with Relapsed or Refractory FL Who Received EPKINLY in Combination with Lenalidomide and Rituximab in EPCORE FL-1 Adverse Reaction Adverse reactions were graded using CTCAE Version 5.0. CRS was graded using ASTCT consensus criteria (Lee et al., 2019). EPKINLY + Lenalidomide and Rituximab Lenalidomide and Rituximab All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) This table includes a combination of grouped and ungrouped terms. (N=131) (N=238) Immune system disorders Cytokine release syndrome 24 The frequency of CRS is based on 131 patients who received EPKINLY at the recommended dosage schedule [see Dosage and Administration (2.2) ] . Grade 1 CRS: 19%; Grade 2 CRS: 5%. The frequency of CRS among the 243 patients who received either the 2-step up or 3-step up dosage schedule was the following: Any grade CRS 35%; Grade 1 CRS: 28%; Grade 2 CRS: 7%. 0 0.8 0 (N=243) (N=238) Skin and subcutaneous tissue disorders Rash Rash includes blister, dermatitis, erythema, rash, skin exfoliation, skin reaction, toxic skin eruption, urticaria and related terms. 46 11 Only Grade 3 adverse reactions occurred. 34 6 Infections and infestations Upper respiratory tract infections Upper respiratory tract infections include sinusitis, laryngitis, nasopharyngitis, pharyngitis, rhinitis, rhinovirus infection, upper respiratory tract infection, and related terms. 33 3.3 18 0.4 Pneumonia Pneumonia includes pneumonia, COVID-19 pneumonia, pneumonia fungal, Pneumocystis jirovecii pneumonia, pneumonia cytomegaloviral, and related terms. 24 16 8 Includes one case with a fatal outcome. 4.6 COVID-19 COVID-19 includes COVID-19, COVID-19 pneumonia, coronavirus infection, coronavirus pneumonia. 23 5 13 1.3 General disorders and administration site conditions Fatigue Fatigue includes asthenia, fatigue, lethargy, malaise. 31 4.9 24 2.1 Injection site reactions 27 0 0.4 0 Fever 23 0.4 11 1.3 Gastrointestinal disorders Constipation 26 0.8 21 0 Mucositis Mucositis includes gingival pain, glossitis, mouth ulceration, mucosal infection, mucosal inflammation, oral discomfort, oral mucosal exfoliation, oropharyngeal pain, stomatitis. 12 0 3.4 0 Nervous system disorders Neurological changes Neurological changes include brain fog, cognitive disorder, confusional state, disturbance in attention, dysphonia, epilepsy, essential tremor, gait disturbance, hypoacusis, lethargy, loss of consciousness, memory impairment, somnolence, syncope, tremor, vertigo, and ICANS. 15 1.2 8 1.3 Headache 11 0 3.8 0 Psychiatric disorders Insomnia 14 0 2.9 0 Other clinically relevant adverse reactions include: Gastrointestinal disorders: diarrhea (26%), nausea (16%), abdominal pain (11%), vomiting (4.1%) Musculoskeletal and connective tissue disorders: musculoskeletal pain (14%), arthralgia (8%) Nervous system disorders: peripheral neuropathy (12%), dizziness (7%), ICANS (0.8%) General disorders: edema (12%) Infections: cytomegalovirus infection (7%), herpesvirus infection (7%), sepsis (2.9%) Blood and lymphatic system disorders: febrile neutropenia (6%) Neoplasms: tumor flare (1.2%) Table 14 summarizes laboratory abnormalities in EPCORE FL-1. Grade 4 laboratory abnormalities in ≥ 2% of the EPKINLY arm included decreases in neutrophils (41%), lymphocytes (13%), and platelets decreased (4.1%). Table 14: Select Laboratory Abnormalities (≥ 30% All Grade and ≥ 10% Higher) That Worsened from Baseline in Patients with Relapsed or Refractory FL Who Received EPKINLY in Combination with Lenalidomide and Rituximab in EPCORE FL-1 Laboratory Abnormality EPKINLY + Lenalidomide and Rituximab The denominator used to calculate the rate varied from 240 to 242 in the EPKINLY arm, and 225 to 236 in the comparator arm, based on the number of patients with a baseline value and at least one post-treatment value. Lenalidomide and Rituximab All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Laboratory abnormalities were graded based on CTCAE Version 5.0 Hematology Neutrophils decreased 86 67 75 41 Lymphocytes decreased 86 62 56 15 Hemoglobin decreased 66 7 52 4.7 Platelets decreased 50 10 37 7 Chemistry Alanine aminotransferase increased 58 7 36 0.9 Phosphate decreased CTCAE Version 5.0 does not include numeric thresholds for grading of hypophosphatemia; all grades represent patients with lab value < Lower Limit of Normal (LLN). 49 N/A 28 N/A Sodium decreased 43 4.1 23 2.6 Potassium decreased 41 9 20 4.7 Aspartate aminotransferase increased 40 2.9 29 0.9 EPCORE NHL-1 The safety of EPKINLY as monotherapy was evaluated in EPCORE NHL-1, a single-arm study of patients with relapsed or refractory FL after two or more lines of systemic therapy who received EPKINLY following a 2-step up dosage schedule (N=127) [see Clinical Studies (14.2) ] . A separate dose optimization cohort evaluated the recommended 3-step up dosage schedule for CRS mitigation (N=86), where EPKINLY was administered via subcutaneous injection until disease progression or unacceptable toxicities according to the following 28-day cycle schedule: Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15, and 48 mg on Day 22 Cycle 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22 Cycles 4-9: EPKINLY 48 mg on Days 1 and 15 Cycles 10 and beyond: EPKINLY 48 mg on Day 1 With the exception of CRS, the safety results presented below and in Tables 15 and 16 represent data from patients who received the 2-step up dosage schedule. The data presented for CRS reflects the 86 patients who received the recommended 3-step up dosage schedule. The study excluded patients with CNS involvement of lymphoma, allogeneic HSCT or solid organ transplant, ongoing active infection, any patients with known impaired T-cell immunity, creatinine clearance < 45 ml/min, alanine aminotransferase > 3 times the upper limit of normal, and a cardiac ejection fraction < 45%. Recommended 3-step up Dosage Schedule Of the 86 patients with relapsed or refractory FL who received EPKINLY following the recommended 3-step up dosage schedule, the median age was 63 years (range: 33 to 90), 57% were male, and 100% had an ECOG performance status of 0 or 1. The median duration of exposure was 5 cycles (range: 1 to 12 cycles). CRS occurred in 49% of patients, with Grade 1 CRS occurring in 45% and Grade 2 in 9% of patients. Serious adverse reactions due to CRS occurred in 28% of patients who received EPKINLY. Dose interruptions due to CRS occurred in 19% of patients who received EPKINLY. 2-step up Dosage Schedule Of the 127 patients with relapsed or refractory FL who received EPKINLY following a 2-step up dosage schedule, the median age was 65 years (range: 39 to 84), 62% were male, and 95% had an ECOG performance status of 0 or 1 [see Clinical Studies (14.2) ] . The median duration of exposure for patients receiving EPKINLY was 8 cycles (range: 1 to 33 cycles). Serious adverse reactions occurred in 66% of patients who received EPKINLY. Serious adverse reactions in ≥ 5% of patients included CRS, COVID-19, pneumonia, and second primary malignancies. Fatal adverse reactions occurred in 9% of patients who received EPKINLY, including COVID-19 (5%), pneumonitis (1.6%), cardiac failure (0.8%), pneumonia (0.8%), and sepsis (0.8%). Permanent discontinuation of EPKINLY due to an adverse reaction occurred in 19% of patients who received EPKINLY. Adverse reactions which resulted in permanent discontinuation of EPKINLY in ≥ 2% of patients included COVID-19, Hepatitis E, pneumonitis, and second primary malignancy. Dosage interruptions of EPKINLY due to an adverse reaction occurred in 59% of patients who received EPKINLY. Adverse reactions which required dosage interruption in ≥ 5% of patients included COVID-19, CRS, pneumonia, upper respiratory tract infection, and fatigue. The most common (≥ 20%) adverse reactions were injection site reactions, CRS, COVID-19, fatigue, upper respiratory tract infection, musculoskeletal pain, rash, diarrhea, pyrexia, cough, and headache. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, and decreased hemoglobin. Table 15 summarizes the adverse reactions in EPCORE NHL-1. Table 15: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory FL Who Received EPKINLY as Monotherapy in EPCORE NHL-1 Adverse Reaction Adverse reactions were graded based on CTCAE Version 5.0. EPKINLY All Grades (%) Grade 3 or 4 (%) (N=86) The frequency of CRS is based on 86 patients with FL who received the recommended 3-step up dosage schedule in EPCORE NHL-1 [see Dosage and Administration (2.2) ] . Immune system disorders Cytokine release syndrome CRS was graded using ASTCT consensus criteria (Lee et al., 2019). The frequency of CRS based on the 127 patients with FL who received the 2-step up dosage schedule in EPCORE NHL-1 was the following: Any grade CRS 66%; Grade 1 CRS: 50%; Grade 2 CRS: 26%; Grade 3 CRS: 1.6%. 49 0 (N=127) General disorders and administration site conditions Injection site reactions Includes related grouped terms. 58 0 Fatigue 37 5 Only Grade 3 adverse reactions occurred. Pyrexia 26 2 Edema 17 0 Infections and Infestations COVID-19 COVID-19 includes COVID-19, COVID-19 pneumonia, SARS-CoV-2 test positive. 40 19 Upper respiratory tract infection Upper respiratory tract infection includes preferred terms with upper respiratory infection and sinusitis, laryngitis viral, nasopharyngitis, oropharyngitis fungal, pharyngitis, rhinitis, rhinovirus infection, tonsillitis. 29 2 Pneumonia Pneumonia includes preferred terms with pneumonia, bronchopulmonary aspergillosis, infectious pleural effusion, infective exacerbation of bronchiectasis, Pneumocystis jirovecii pneumonia, pneumonia respiratory syncytial viral. 17 13 Urinary tract infection 13 5 Herpesvirus infection Herpesvirus infection includes herpes simplex, herpes simplex reactivation, herpes virus infection, herpes zoster, oral herpes, varicella zoster virus infection. 12 1.6 Musculoskeletal and connective tissue disorders Musculoskeletal pain 28 0.8 Arthralgia 14 0.8 Skin and subcutaneous disorders Rash 28 0 Gastrointestinal disorders Diarrhea 26 1.6 Nausea 17 0 Abdominal pain 17 0.8 Constipation 16 0 Mucositis Mucositis includes aphthous ulcer, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal pain, stomatitis, tongue ulceration. 12 0 Respiratory disorders Cough 20 0 Dyspnea 17 0 Nervous system disorders Headache 20 0 Neurological changes Neurological changes includes amnesia, aphasia, balance disorder, brain fog, confusional state, dysphonia, encephalopathy, extrapyramidal disorder, hallucination, hypoacusis, memory impairment, mental status changes, tremor, vertigo. 13 0 Peripheral neuropathy and paresthesia Peripheral neuropathy and paresthesia includes bell's palsy, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy, polyneuropathy. 13 1.6 Dizziness 11 0 Psychiatric disorders Insomnia 13 0 Renal and urinary disorders Renal insufficiency Renal insufficiency includes acute kidney injury, blood creatinine increased, renal impairment. 10 1.6 Clinically relevant adverse reactions in < 10% of patients (N=127) who received EPKINLY included vomiting, pruritus, hepatotoxicity, ICANS, lower respiratory tract infections, cardiac arrhythmias, respiratory tract infections, pneumonitis, second primary malignancy, vision changes, cellulitis, febrile neutropenia, cardiac failure, cytomegalovirus infection and sepsis. Table 16 summarizes laboratory abnormalities in EPCORE NHL-1. Table 16: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Relapsed or Refractory FL Who Received EPKINLY in EPCORE NHL-1 Laboratory Abnormality Laboratory abnormalities were graded based on CTCAE Version 5.0 EPKINLY The denominator used to calculate the rate varied from 123 to 127 based on the number of patients with a baseline value and at least one post-treatment value. (N=127) All Grades Grade 3 or 4 (%) Hematology Lymphocytes decreased 94 82 Hemoglobin decreased 59 10 White blood cells decreased 58 19 Neutrophils decreased 55 30 Platelets decreased 49 8 Chemistry Sodium decreased 51 1.6 ALT increased 47 8 AST increased 44 6 Creatinine increased 36 0.8 Alkaline phosphatase increased 29 0 Bilirubin increased 28 1.6 Potassium decreased 20 3.1 Magnesium decreased 20 0.8 6.2 Postmarketing Experience The following adverse reaction has been identified during post-approval use of EPKINLY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune system disorders : Hemophagocytic Lymphohistiocytosis (HLH)"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY. Epcoritamab-bysp causes release of cytokines [see Clinical Pharmacology (12.2) ] that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY and up to 14 days after the first 48 mg dose, and during and after CRS [see Warnings and Precautions (5.1) ] ."],"how_supplied_table":["
Carton contentsNDC number
One 4 mg/0.8 mL single-dose vialNDC 82705-002-01
One 48 mg/0.8 mL single-dose vialNDC 82705-010-01
"],"spl_medguide_table":["
This Medication Guide has been approved by the U.S. Food and Drug Administration.Revised: Mar 2026
MEDICATION GUIDE EPKINLY® (ep-KIN-lee) (epcoritamab-bysp) injection, for subcutaneous use
What is the most important information I should know about EPKINLY? EPKINLY can cause serious side effects, including:Cytokine Release Syndrome (CRS). CRS is common during treatment with EPKINLY and can also be serious or lead to death. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:
fever of 100.4°F (38°C) or higherdizziness or light-headednesstrouble breathingchillsfast heartbeatfeeling anxiousheadacheconfusionshaking (tremors)problems with balance and movement, such as trouble walking
Due to the risk of CRS, you will receive EPKINLY on a "step-up dosing schedule".The step-up dosing schedule is when you receive 2 or 3 smaller "step-up" doses of EPKINLY during your first cycle of treatment (Cycle 1).You will receive your first full dose of EPKINLY a week after your last step-up dose (this will be Day 15 or Day 22 of Cycle 1).If your dose of EPKINLY is delayed for any reason, you may need to repeat the "step-up dosing schedule".Before each dose in Cycle 1, you will receive medicines to help reduce your risk of CRS. You will also receive medicine for 3 days after each dose in Cycle 1. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.See "How will I receive EPKINLY?" for more information about how you will receive EPKINLY.
Neurologic problems. EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:
trouble speaking or writingconfusion and disorientationdrowsinesstiredness or lack of energymuscle weaknessshaking (tremors)seizuresmemory loss
Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe. People with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems. People with follicular lymphoma (FL) may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems. See "What are the possible side effects of EPKINLY?" for more information about side effects.
What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with: certain types of DLBCL or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory),after 2 or more treatments.follicular lymphoma that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab.follicular lymphoma that has come back or that did not respond after 2 or more treatments. It is not known if EPKINLY is safe and effective in children.
Before receiving EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:have an infection.are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby. Females who are able to become pregnant:Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY.You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY.Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY.are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of EPKINLY.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive EPKINLY?EPKINLY will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in the lower part of your stomach-area (abdomen) or thigh.Your EPKINLY treatment schedule is divided into cycles that are usually 28 days (4 weeks) long.Your healthcare provider will decide how many treatment cycles you will receive and how often you will receive EPKINLY in each cycle.See "What is the most important information I should know about EPKINLY?" for more information about how you will receive EPKINLY.
What should I avoid while receiving EPKINLY? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. See "What is the most important information I should know about EPKINLY?" for more information about signs and symptoms of CRS and neurologic problems.
What are the possible side effects of EPKINLY? EPKINLY can cause serious side effects, including:See "What is the most important information I should know about EPKINLY?"Infections. EPKINLY can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment with EPKINLY. Your healthcare provider should prescribe medicines before you start treatment to help prevent infection and treat you as needed if you develop an infection during treatment with EPKINLY. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with EPKINLY, including:
fever of 100.4°F (38°C) or highercoughchest paintirednessshortness of breathpainful rashsore throatpain during urinationfeeling weak or generally unwellconfusion
Low blood cell counts. EPKINLY can cause low blood cell counts which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment with EPKINLY. EPKINLY may cause the following low blood cell counts: low white blood cell counts (neutropenia and lymphopenia). Low white blood cells can increase your risk for infection.low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath.low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include:
CRSinjection site reactionstirednessmuscle and bone painfeverdiarrheaCOVID-19rashstomach area (abdominal pain)
The most common severe abnormal laboratory test results with EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include: decreased white blood cells, decreased red blood cells, and decreased platelets.
The most common side effects of EPKINLY when used together with lenalidomide and rituximab in follicular lymphoma include:
rashupper respiratory tract infectionstirednessinjection site reactionsconstipationdiarrheaCRSpneumoniaCOVID-19fever
The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab in follicular lymphoma include: decreased white blood cells and decreased platelets. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about safe and effective use of EPKINLY. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about EPKINLY that is written for health professionals.
What are the ingredients in EPKINLY? Active ingredient: epcoritamab-bysp Inactive ingredients: acetic acid, polysorbate 80, sodium acetate, sorbitol and Water for Injection. Manufactured by: Genmab US, Inc., Plainsboro, NJ 08536 U.S. License Number: 2293 Marketed by: Genmab US, Inc., Plainsboro, NJ 08536 and AbbVie Inc., North Chicago, IL 60064 EPKINLY is a registered trademark owned by Genmab A/S ©2026 Genmab A/S For more information, go to www.EPKINLY.com or call 1-855-4GENMAB (1-855-443-6622)
"],"mechanism_of_action":["12.1 Mechanism of Action Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. In vitro, epcoritamab-bysp activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells. In nonclinical studies, the combination of epcoritamab-bysp and rituximab resulted in both T-cell mediated cytotoxicity and natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC)."],"recent_major_changes":["Indications and Usage ( 1.2 ) 11/2025 Dosage and Administration ( 2.1 ) 3/2026 Dosage and Administration ( 2.2 , 2.5 , 2.6 ) 11/2025 Warnings and Precautions ( 5.1 ) 3/2026 Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) 11/2025 Warnings and Precautions, Infections ( 5.3 ) 9/2025"],"storage_and_handling":["Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light. Do not freeze. Do not shake."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. In vitro, epcoritamab-bysp activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells. In nonclinical studies, the combination of epcoritamab-bysp and rituximab resulted in both T-cell mediated cytotoxicity and natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC). 12.2 Pharmacodynamics Circulating B-Cell Count Circulating B-cells decreased to undetectable levels (< 10 cells/microliter) after administration of the approved recommended dosage of EPKINLY in patients who had detectable B-cells at treatment initiation by Cycle 1 Day 15 and the depletion was sustained while patients remained on treatment. Cytokine Concentrations Plasma concentrations of cytokines (IL-2, IL-6, IL-10, TNF-α, and IFN-γ) were measured. Transient elevation of circulating cytokines was observed at dose levels of 0.04 mg and above. After administration of the approved recommended dosages of EPKINLY, cytokine levels increased within 24 hours after the first dose on Cycle 1 Day 1, generally reached maximum levels after the first 48 mg dose, and returned to baseline prior to the second 48 mg full dose. 12.3 Pharmacokinetics Pharmacokinetic (PK) parameters were evaluated at the approved recommended dosage (48 mg) and are presented as geometric mean (CV%) unless otherwise specified. Epcoritamab-bysp area under the concentration-time curve (AUC) increased more than proportionally over a full dosage range from 1.5 to 60 mg (0.03125 to 1.25 times the approved recommended dosage). Epcoritamab-bysp maximum concentration (10.2 mcg/mL [43.2%]) is achieved after the first dose of the Q2W regimen (i.e., the first dose of Cycle 4). No clinically significant differences in pharmacokinetic parameters were observed between patients with relapsed or refractory LBCL and patients with relapsed or refractory FL. PK exposures are summarized for the recommended dosage of EPKINLY in Table 17. Table 17: Exposure Parameters of Epcoritamab-bysp in Subjects with Relapsed or Refractory LBCL or FL Following Recommended Dosage C avg (mcg/mL) Values are geometric mean with geometric CV%. C max (mcg/mL) C trough (mcg/mL) First full 48 mg dose First full 48 mg dose is on the first day of Week 3 in subjects with relapsed or refractory LBCL and on the first day of Week 4 in subjects with relapsed or refractory FL. 1.3 (113.3%) 1.7 (106.7%) 1.4 (100.9%) End of weekly dosing (end of Cycle 3) 9.1 (45.9%) 9.9 (43.4%) 7.8 (52.4%) End of every 2-week dosing (end of Cycle 9) 5.3 (57%) 6.7 (49.4%) 3.6 (81.5%) Steady state Steady state values are approximated at Cycle 15 (Week 60). with every 4-week dosing 2.4 (73.3%) 4.2 (59.8%) 1.1 (134.1%) Absorption The median (range) T max of epcoritamab-bysp after the first full dose and end of the weekly dosing regimen (end of Cycle 3) treatment doses were 4 (0.3 to 7) days and 2.3 (0.3 to 3.2) days, respectively. Distribution The apparent total volume of distribution is 25.6 L (82%). Elimination The half-life of full dose epcoritamab-bysp (48 mg) was approximately 22 days (58%) at the end of Cycle 3, with apparent total clearance of approximately 0.53 L/day (40%) after the end of Cycle 3. Metabolism Epcoritamab-bysp is expected to be metabolized into small peptides by catabolic pathways. Specific Populations No clinically significant differences in the PK of epcoritamab-bysp were observed based on age (20 to 89 years), sex, race (White or Asian), mild to moderate renal impairment (creatinine clearance [CLcr] 30 to < 90 mL/min as estimated by Cockcroft-Gault formula), and mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin 1 to 1.5 times ULN and any AST) after accounting for differences in bodyweight. The effects of severe renal impairment (CLcr 15 to < 30 mL/min), end-stage renal disease (CLcr < 15 mL/min), or moderate to severe hepatic impairment (total bilirubin > 1.5 times ULN and any AST) on the PK of epcoritamab-bysp are unknown. Body Weight In patients who received the recommended dosage of EPKINLY, geometric mean average concentration following the first full 48 mg dose was 31% lower in the higher body weight (BW) group (85 to 172 kg) and 13% higher in the lower BW group (39 to 65 kg) compared to patients with BW of 65 to less than 85 kg. Drug Interaction Studies No clinical studies evaluating the drug interaction potential of epcoritamab-bysp have been conducted. 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies (ADA) in the study described below with the incidence of ADA in other studies, including those of epcoritamab-bysp. Anti-epcoritamab-bysp antibodies developed in 2.6% of patients (4 of 156) with LBCL and 4.2% of patients (8 of 190) with FL treated with EPKINLY in EPCORE NHL-1 (up to 10 cycles) [see Clinical Studies (14.1 , 14.2) ] using an electrochemiluminescence immunoassay (ECLIA). Anti-epcoritamab-bysp antibodies developed in 2.1% of patients (5 of 236) with FL treated with EPKINLY in combination with lenalidomide and rituximab in EPCORE FL-1 (up to 12 cycles) [see Clinical Studies (14.2) ] using an ECLIA. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the PK, pharmacodynamics, safety, and effectiveness of epcoritamab-bysp is unknown."],"indications_and_usage":["1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Infections: Can cause fatal or serious infections. Monitor patients for signs or symptoms of infection, including opportunistic infections, and treat appropriately. ( 5.3 ) Cytopenias: Monitor complete blood cell counts during treatment. ( 5.4 ) Embryo-Fetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. ( 5.5 , 8.1 , 8.3 ) 5.1 Cytokine Release Syndrome EPKINLY can cause CRS, including serious or fatal reactions [see Adverse Reactions (6.1) ] . Relapsed or Refractory Large B-cell Lymphoma CRS occurred in 51% (80/157) of patients with LBCL receiving EPKINLY at the recommended dosage schedule in EPCORE NHL-1, with Grade 1 CRS occurring in 37%, Grade 2 in 17%, and Grade 3 in 2.5% of patients. Recurrent CRS occurred in 31% of these patients. Most CRS events (92%) occurred during Cycle 1. In Cycle 1, CRS events occurred in 6% of patients after the 0.16 mg dose, 12% after the 0.8 mg dose, 43% after the first 48 mg dose, and 5% after the next 48 mg dose. The median time to onset of CRS from the most recent EPKINLY dose was 24 hours (range: 0 to 10 days). The median time to onset after the first 48 mg dose was 21 hours (range: 0 to 7 days). For patients with LBCL, assess whether hospitalization or outpatient monitoring for the first 48 mg dose (Cycle 1 Day 15) is appropriate based on comorbidities or other situational factors [see Dosage and Administration (2.1) ]. During outpatient monitoring after the first 48 mg dose, patients should remain in proximity to a healthcare facility that can assess and manage CRS. Relapsed or Refractory Follicular Lymphoma CRS occurred in 49% (42/86) of patients with FL receiving EPKINLY monotherapy at the recommended dosage schedule in EPCORE NHL-1, with Grade 1 CRS occurring in 45% and Grade 2 in 9% of patients. Recurrent CRS occurred in 48% of patients. Most CRS events (88%) occurred during Cycle 1. In Cycle 1, CRS events occurred in 12% of patients after the 0.16 mg dose, 6% after the 0.8 mg dose, 15% after the 3 mg dose, and 37% after the first 48 mg dose. The median time to onset of CRS from the most recent EPKINLY dose was 59 hours (range: 0.1 to 7 days). The median time to onset after the first 48 mg dose was 61 hours (range: 0.1 to 7 days). CRS occurred in 24% (32/131) of patients with FL receiving EPKINLY at the recommended dosage schedule in combination with lenalidomide and rituximab in EPCORE FL-1, with Grade 1 CRS occurring in 19%, Grade 2 in 5% of patients, and serious adverse reactions due to CRS in 12%. Recurrent CRS occurred in 41% of patients. Most CRS events (88%) occurred during Cycle 1. In Cycle 1, CRS occurred in 5% of patients after the 0.16 mg dose, 3.8% after the 0.8 mg dose, 2.3% after the 3 mg dose, and 18% after the first 48 mg dose. The median time to onset of CRS from the most recent EPKINLY dose was 78 hours (range: 0.2 to 12 days). The median time to onset after the first 48 mg dose was 41 hours (range: 0.3 to 12 days). For patients with FL, assess whether hospitalization or outpatient monitoring for the first 48 mg dose (Cycle 1 Day 22) is appropriate based on comorbidities or other situational factors [see Dosage and Administration (2.1) ] . During outpatient monitoring after the first 48 mg dose, patients should remain in proximity to a healthcare facility that can assess and manage CRS. Among patients with LBCL or FL who experienced CRS, signs and symptoms included pyrexia, hypotension, hypoxia, dyspnea, chills, and tachycardia. CRS resolved in 98% of patients, after a median duration of 2 days (range: < 1 to 27 days). Concurrent neurological adverse reactions associated with CRS occurred in 2.5% of patients with LBCL, 4.7% of patients with FL receiving EPKINLY monotherapy, and 1.5% of patients receiving EPKINLY in combination with lenalidomide and rituximab. Concurrent neurological adverse reactions included headache, confusional state, tremors, dizziness, and ataxia. Initiate EPKINLY according to the recommended step-up dosage schedule. Administer pretreatment medications to reduce the risk of CRS and monitor patients for potential CRS accordingly [see Dosage and Administration (2.2 , 2.3 , 2.4) ] . At the first signs or symptoms of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care as appropriate. Withhold or discontinue EPKINLY based on the severity of CRS [see Dosage and Administration (2.6) ] . Patients who experience CRS (or other adverse reactions that impair consciousness) should be evaluated and advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution. 5.2 Immune Effector Cell-Associated Neurotoxicity Syndrome EPKINLY can cause life-threatening and fatal immune effector cell-associated neurotoxicity syndrome (ICANS) [see Adverse Reactions (6.1) ] . Relapsed or Refractory Large B-cell Lymphoma ICANS occurred in 6% (10/157) of patients with LBCL receiving EPKINLY at the recommended dosage schedule in EPCORE NHL-1, with Grade 1 ICANS in 4.5% and Grade 2 ICANS in 1.3% of patients. There was one (0.6%) fatal ICANS occurrence. Of the 10 ICANS events, 9 occurred within Cycle 1 of EPKINLY treatment, with a median time to onset of ICANS of 16.5 days (range: 8 to 141 days) from the start of treatment. Relative to the most recent administration of EPKINLY, the median time to onset of ICANS was 3 days (range: 1 to 13 days). The median duration of ICANS was 4 days (range: 0 to 8 days) with ICANS resolving in 90% of patients with supportive care. Relapsed or Refractory Follicular Lymphoma ICANS occurred in 6% (8/127) of patients with FL receiving EPKINLY monotherapy following the 2-step up dosage schedule in EPCORE NHL-1, with Grade 1 ICANS in 3.9% and Grade 2 ICANS in 2.4% of patients. The median time to onset of ICANS was 22 days (range: 14 to 66 days) from the start of treatment. Relative to the most recent administration of EPKINLY, the median time to onset of ICANS was 3 days (range: 0.4 to 7 days). The median duration of ICANS was 2 days (range: 1 to 7 days) with ICANS resolving in 100% of patients. Among patients with FL who received EPKINLY at the recommended dosage schedule in combination with lenalidomide and rituximab in EPCORE FL-1, ICANS occurred in 0.8% (1/131, Grade 1). For patients with LBCL or FL, clinical manifestations of ICANS included, but were not limited to confusional state, lethargy, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for potential ICANS following EPKINLY. At the first signs or symptoms of ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or discontinue EPKINLY per recommendations and consider further management per current practice guidelines [see Dosage and Administration (2.6) ] . Patients who experience signs or symptoms of ICANS or any other adverse reactions that impair cognition or consciousness should be evaluated, including potential neurology evaluation, and patients at increased risk should be advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution. 5.3 Infections EPKINLY can cause fatal and serious infections [see Adverse Reactions (6.1) ] . Serious infections, including opportunistic infections, were reported in 15% of patients with LBCL receiving EPKINLY at the recommended dosage schedule in EPCORE NHL-1 and were most commonly due to sepsis (4.5%) and pneumonia (3.2%). Fatal infections occurred in 1.3% of patients and were due to COVID-19. Serious infections, including opportunistic infections, were reported in 40% of patients with FL receiving EPKINLY monotherapy following the 2-step up dosage schedule in EPCORE NHL-1 and were most commonly due to COVID-19 (20%), pneumonia (13%), and urinary tract infections (3%). Fatal infections occurred in 6% of patients and included COVID-19 (5%), pneumonia (0.8%), and sepsis (0.8%). Among 243 patients with FL who received EPKINLY in combination with lenalidomide and rituximab in EPCORE FL-1, serious infections occurred in 28% of patients. The most common serious infections were pneumonia (15%), COVID-19 (7%), opportunistic infections (5%) and upper respiratory infections (3.3%). The most common opportunistic infections of any grade were CMV infection (7%) and herpesvirus infection (7%). Progressive multifocal leukoencephalopathy (PML), including fatal cases, has occurred in patients treated with EPKINLY. Across a broader clinical trial population, PML was reported in 0.4% (11/3072) of patients, including in the first-line treatment setting. Of the 11 cases of PML, six resulted in fatal outcomes and one was unresolved at the time of death. Monitor patients for signs and symptoms of infection and treat appropriately. Avoid administration of EPKINLY in patients with active infections. Provide PJP prophylaxis during treatment with EPKINLY, and consider initiating prophylaxis against herpesvirus [see Dosage and Administration (2.5) ]. Withhold or consider permanent discontinuation of EPKINLY based on severity [see Dosage and Administration (2.6) ] . 5.4 Cytopenias EPKINLY can cause serious or severe cytopenias, including neutropenia, lymphopenia, anemia, and thrombocytopenia [see Adverse Reactions (6.1) ] . In patients with LBCL who received EPKINLY at the recommended dosage schedule, Grade 3 or 4 decreased neutrophils occurred in 32% (Grade 4, 14%), decreased hemoglobin in 12% (Grade 4, 0%), and decreased platelets in 12% (Grade 4, 7%) of patients. Febrile neutropenia occurred in 2.5% (Grade 4, 0.6%). In patients with FL who received EPKINLY monotherapy following the 2-step up dosage schedule, Grade 3 or 4 decreased neutrophils occurred in 30% (Grade 4, 17%), decreased hemoglobin in 10% (Grade 4, 0%), and decreased platelets in 8% of patients (Grade 4, 4%). Febrile neutropenia occurred in 3.1% (Grade 4, 0%). In patients with FL who received EPKINLY in combination with lenalidomide and rituximab, Grade 3 or 4 decreased neutrophils occurred in 67% (Grade 4, 41%), decreased lymphocytes in 62% (Grade 4, 13%), decreased hemoglobin in 7%, and decreased platelets in 10% (Grade 4, 4.1%) of patients. Febrile neutropenia occurred in 6% (Grade 4, 2.1%). Monitor complete blood counts throughout treatment. Based on the severity of cytopenias, temporarily withhold or permanently discontinue EPKINLY [see Dosage and Administration (2.6) ]. Consider prophylactic granulocyte colony-stimulating factor administration as applicable. 5.5 Embryo-Fetal Toxicity Based on its mechanism of action, EPKINLY may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with EPKINLY and for 4 months after the last dose [see Use in Specific Populations (8.1 , 8.3) ] ."],"clinical_studies_table":["
Table 18: Efficacy Results in EPCORE NHL-1 in Patients with DLBCL and High-grade B-cell Lymphoma
EndpointDetermined by Lugano criteria (2014) as assessed by independent review committee (IRC).EPKINLY (N=148)
ORR = overall response rate; CI = confidence interval; CR = complete response; PR = partial response; DOR = duration of response; NR = not reached.
ORREarly response assessments were evaluated in the context of potential flare reactions. Of 90 patients who achieved an objective response, 9 patients had early flare reactions identified with objective response demonstrated on subsequent imaging per Lugano criteria., n (%)90 (61)
(95% CI)(52.5, 68.7)
CR, n (%)56 (38)
(95% CI)(30.0, 46.2)
PR, n (%)34 (23)
(95% CI)(16.5, 30.6)
DOR
Median (95% CI), months15.6 (9.7, NR)
9-month estimateKaplan-Meier estimate. (95% CI), %63 (51.5, 72.4)
","
Table 19: Efficacy Results in EPCORE FL-1 in Patients with FL
Outcome per IRCEPKINLY + Lenalidomide and Rituximab (N=243)Lenalidomide and Rituximab (N=245)
PFS = progression free survival; CI = confidence interval; NR = not reached; ORR = overall response rate; CR = complete response.
PFS
Number of events, n (%)23 (9)75 (31)
Progressive disease19 (83)63 (84)
Death4 (17)12 (16)
Median (95% CI), monthsNR (21.9, NR)11.2 (10.5, NR)
Hazard ratioCox proportional hazards hazard ratio stratified by disease history and region. (95% CI)0.21 (0.13, 0.33)
P-valueLog-rank p-value (one sided) stratified by disease history and region.< 0.0001
ORR, n (%)216 (89)181 (74)
(95% CI)(84, 93)(68, 79)
P-valueP-value is based on a prespecified analysis of the first 232 patients randomized.,P-value (one sided) is from a Cochran-Mantel-Haenszel test stratified by disease history and region.< 0.0001
CR, n (%)181 (74)106 (43)
(95% CI)(69, 80)(37, 50)
P-value< 0.0001
","
Table 20: Efficacy Results in EPCORE NHL-1 in Patients with FL
EndpointDetermined by Lugano criteria (2014) as assessed by independent review committee (IRC).EPKINLY (N=127)
ORR = overall response rate; CI = confidence interval; CR = complete response; PR = partial response; DOR = duration of response; NR = not reached.
ORR, n (%)104 (82)
(95% CI)(74.1, 88.2)
CR, n (%)76 (60)
(95% CI)(50.8, 68.4)
PR, n (%)28 (22)
(95% CI)(15.2, 30.3)
DOR
Median (95% CI), monthsNR (13.7, NR)
12-month estimateKaplan-Meier estimate. % (95% CI)68.4 (57.6, 77.0)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity or genotoxicity studies have been conducted with epcoritamab-bysp. No dedicated studies have been conducted to evaluate the effects of epcoritamab-bysp on fertility."],"pharmacokinetics_table":["
Table 17: Exposure Parameters of Epcoritamab-bysp in Subjects with Relapsed or Refractory LBCL or FL Following Recommended Dosage
Cavg (mcg/mL)Values are geometric mean with geometric CV%.Cmax (mcg/mL)Ctrough (mcg/mL)
First full 48 mg doseFirst full 48 mg dose is on the first day of Week 3 in subjects with relapsed or refractory LBCL and on the first day of Week 4 in subjects with relapsed or refractory FL.1.3 (113.3%)1.7 (106.7%)1.4 (100.9%)
End of weekly dosing (end of Cycle 3)9.1 (45.9%)9.9 (43.4%)7.8 (52.4%)
End of every 2-week dosing (end of Cycle 9)5.3 (57%)6.7 (49.4%)3.6 (81.5%)
Steady stateSteady state values are approximated at Cycle 15 (Week 60). with every 4-week dosing2.4 (73.3%)4.2 (59.8%)1.1 (134.1%)
"],"adverse_reactions_table":["
Table 11: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory LBCL Who Received EPKINLY in EPCORE NHL-1
EPKINLY (N=157)
Adverse ReactionAdverse reactions were graded based on CTCAE Version 5.0All Grades (%)Grade 3 or 4 (%)
Immune system disorders
Cytokine release syndromeCRS was graded using ASTCT consensus criteria (Lee et al., 2019).512.5Only grade 3 adverse reactions occurred.
General disorders and administration site conditions
FatigueFatigue includes asthenia, fatigue, lethargy.292.5
Injection site reactionsInjection site reaction includes injection site erythema, injection site hypertrophy, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, injection site urticaria.270
Pyrexia240
EdemaEdema includes edema, edema peripheral, face edema, generalized edema, peripheral swelling.141.9
Musculoskeletal and connective tissue disorders
Musculoskeletal painMusculoskeletal pain includes back pain, bone pain, flank pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain, pain in extremity, spinal pain.281.3
Gastrointestinal disorders
Abdominal painAbdominal pain includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness.231.9
Diarrhea200
Nausea201.3
Vomiting120.6
Skin and subcutaneous disorders
RashRash includes dermatitis bullous, erythema, palmar erythema, penile erythema, rash, rash erythematous, rash maculo-papular, rash pustular, recall phenomenon, seborrheic dermatitis, skin exfoliation.150.6
Nervous system disorder
Headache130.6
Metabolism and nutrition disorders
Decreased appetite120.6
Cardiac disorders
Cardiac arrhythmiasCardiac arrhythmias includes bradycardia, sinus bradycardia, sinus tachycardia, supraventricular extrasystoles, supraventricular tachycardia, tachycardia.100.6
","
Table 12: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Relapsed or Refractory LBCL Who Received EPKINLY in EPCORE NHL-1
Laboratory AbnormalityLaboratory abnormalities were graded based on CTCAE Version 5.0EPKINLYThe denominator used to calculate the rate varied from 146 to 153 based on the number of patients with a baseline value and at least one post-treatment value.
All Grades (%)Grade 3 or 4 (%)
Hematology
Lymphocyte count decreased8777
Hemoglobin decreased6212
White blood cells decreased5322
Neutrophils decreased5032
Platelets decreased4812
Chemistry
Sodium decreased562.6
Phosphate decreasedCTCAE Version 5.0 does not include numeric thresholds for grading of hypophosphatemia; all grades represent patients with lab value < Lower Limit of Normal (LLN).56N/A
Aspartate aminotransferase increased484.6
Alanine aminotransferase increased455.3
Potassium decreased345.3
Magnesium decreased310
Creatinine increased243.3
Potassium increased211.3
","
Table 13: Adverse Reactions (≥ 10% All Grade and ≥ 5% Higher) in Patients with Relapsed or Refractory FL Who Received EPKINLY in Combination with Lenalidomide and Rituximab in EPCORE FL-1
Adverse ReactionAdverse reactions were graded using CTCAE Version 5.0. CRS was graded using ASTCT consensus criteria (Lee et al., 2019).EPKINLY + Lenalidomide and RituximabLenalidomide and Rituximab
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
This table includes a combination of grouped and ungrouped terms.
(N=131)(N=238)
Immune system disorders
Cytokine release syndrome24The frequency of CRS is based on 131 patients who received EPKINLY at the recommended dosage schedule [see Dosage and Administration (2.2)]. Grade 1 CRS: 19%; Grade 2 CRS: 5%.The frequency of CRS among the 243 patients who received either the 2-step up or 3-step up dosage schedule was the following: Any grade CRS 35%; Grade 1 CRS: 28%; Grade 2 CRS: 7%.00.80
(N=243)(N=238)
Skin and subcutaneous tissue disorders
RashRash includes blister, dermatitis, erythema, rash, skin exfoliation, skin reaction, toxic skin eruption, urticaria and related terms.4611Only Grade 3 adverse reactions occurred.346
Infections and infestations
Upper respiratory tract infectionsUpper respiratory tract infections include sinusitis, laryngitis, nasopharyngitis, pharyngitis, rhinitis, rhinovirus infection, upper respiratory tract infection, and related terms.333.3180.4
PneumoniaPneumonia includes pneumonia, COVID-19 pneumonia, pneumonia fungal, Pneumocystis jirovecii pneumonia, pneumonia cytomegaloviral, and related terms.24168Includes one case with a fatal outcome.4.6
COVID-19COVID-19 includes COVID-19, COVID-19 pneumonia, coronavirus infection, coronavirus pneumonia.235131.3
General disorders and administration site conditions
FatigueFatigue includes asthenia, fatigue, lethargy, malaise.314.9242.1
Injection site reactions2700.40
Fever230.4111.3
Gastrointestinal disorders
Constipation260.8210
MucositisMucositis includes gingival pain, glossitis, mouth ulceration, mucosal infection, mucosal inflammation, oral discomfort, oral mucosal exfoliation, oropharyngeal pain, stomatitis.1203.40
Nervous system disorders
Neurological changesNeurological changes include brain fog, cognitive disorder, confusional state, disturbance in attention, dysphonia, epilepsy, essential tremor, gait disturbance, hypoacusis, lethargy, loss of consciousness, memory impairment, somnolence, syncope, tremor, vertigo, and ICANS.151.281.3
Headache1103.80
Psychiatric disorders
Insomnia1402.90
","
Table 14: Select Laboratory Abnormalities (≥ 30% All Grade and ≥ 10% Higher) That Worsened from Baseline in Patients with Relapsed or Refractory FL Who Received EPKINLY in Combination with Lenalidomide and Rituximab in EPCORE FL-1
Laboratory AbnormalityEPKINLY + Lenalidomide and RituximabThe denominator used to calculate the rate varied from 240 to 242 in the EPKINLY arm, and 225 to 236 in the comparator arm, based on the number of patients with a baseline value and at least one post-treatment value.Lenalidomide and Rituximab
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
Laboratory abnormalities were graded based on CTCAE Version 5.0
Hematology
Neutrophils decreased86677541
Lymphocytes decreased86625615
Hemoglobin decreased667524.7
Platelets decreased5010377
Chemistry
Alanine aminotransferase increased587360.9
Phosphate decreasedCTCAE Version 5.0 does not include numeric thresholds for grading of hypophosphatemia; all grades represent patients with lab value < Lower Limit of Normal (LLN).49N/A28N/A
Sodium decreased434.1232.6
Potassium decreased419204.7
Aspartate aminotransferase increased402.9290.9
","
Table 15: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory FL Who Received EPKINLY as Monotherapy in EPCORE NHL-1
Adverse ReactionAdverse reactions were graded based on CTCAE Version 5.0.EPKINLY
All Grades (%)Grade 3 or 4 (%)
(N=86)The frequency of CRS is based on 86 patients with FL who received the recommended 3-step up dosage schedule in EPCORE NHL-1 [see Dosage and Administration (2.2)].
Immune system disorders
Cytokine release syndromeCRS was graded using ASTCT consensus criteria (Lee et al., 2019).The frequency of CRS based on the 127 patients with FL who received the 2-step up dosage schedule in EPCORE NHL-1 was the following: Any grade CRS 66%; Grade 1 CRS: 50%; Grade 2 CRS: 26%; Grade 3 CRS: 1.6%.490
(N=127)
General disorders and administration site conditions
Injection site reactionsIncludes related grouped terms.580
Fatigue375Only Grade 3 adverse reactions occurred.
Pyrexia262
Edema170
Infections and Infestations
COVID-19COVID-19 includes COVID-19, COVID-19 pneumonia, SARS-CoV-2 test positive.4019
Upper respiratory tract infectionUpper respiratory tract infection includes preferred terms with upper respiratory infection and sinusitis, laryngitis viral, nasopharyngitis, oropharyngitis fungal, pharyngitis, rhinitis, rhinovirus infection, tonsillitis.292
PneumoniaPneumonia includes preferred terms with pneumonia, bronchopulmonary aspergillosis, infectious pleural effusion, infective exacerbation of bronchiectasis, Pneumocystis jirovecii pneumonia, pneumonia respiratory syncytial viral.1713
Urinary tract infection135
Herpesvirus infectionHerpesvirus infection includes herpes simplex, herpes simplex reactivation, herpes virus infection, herpes zoster, oral herpes, varicella zoster virus infection.121.6
Musculoskeletal and connective tissue disorders
Musculoskeletal pain280.8
Arthralgia140.8
Skin and subcutaneous disorders
Rash280
Gastrointestinal disorders
Diarrhea261.6
Nausea170
Abdominal pain170.8
Constipation160
MucositisMucositis includes aphthous ulcer, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal pain, stomatitis, tongue ulceration.120
Respiratory disorders
Cough200
Dyspnea170
Nervous system disorders
Headache200
Neurological changesNeurological changes includes amnesia, aphasia, balance disorder, brain fog, confusional state, dysphonia, encephalopathy, extrapyramidal disorder, hallucination, hypoacusis, memory impairment, mental status changes, tremor, vertigo.130
Peripheral neuropathy and paresthesiaPeripheral neuropathy and paresthesia includes bell's palsy, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy, polyneuropathy.131.6
Dizziness110
Psychiatric disorders
Insomnia130
Renal and urinary disorders
Renal insufficiencyRenal insufficiency includes acute kidney injury, blood creatinine increased, renal impairment.101.6
","
Table 16: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with Relapsed or Refractory FL Who Received EPKINLY in EPCORE NHL-1
Laboratory AbnormalityLaboratory abnormalities were graded based on CTCAE Version 5.0EPKINLYThe denominator used to calculate the rate varied from 123 to 127 based on the number of patients with a baseline value and at least one post-treatment value. (N=127)
All GradesGrade 3 or 4 (%)
Hematology
Lymphocytes decreased9482
Hemoglobin decreased5910
White blood cells decreased5819
Neutrophils decreased5530
Platelets decreased498
Chemistry
Sodium decreased511.6
ALT increased478
AST increased446
Creatinine increased360.8
Alkaline phosphatase increased290
Bilirubin increased281.6
Potassium decreased203.1
Magnesium decreased200.8
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Cytokine Release Syndrome (CRS) Inform patients of the risk of CRS, and to immediately contact their healthcare provider should signs and symptoms associated with CRS (e.g., pyrexia, hypotension, hypoxia, chills, tachycardia, headache, and dyspnea) occur at any time. Advise patients with DLBCL or high-grade B-cell lymphoma that they may be hospitalized after administration of the Cycle 1 Day 15 dosage of 48 mg and patients with FL after administration of the Cycle 1 Day 22 dosage of 48 mg. Patients who receive Cycle 1 Day 15 and patients who receive Cycle 1 Day 22 first full dosage of 48 mg at an outpatient facility should remain in proximity of a healthcare facility that can assess and manage CRS afterwards. Advise all patients who experience symptoms that impair consciousness not to drive and refrain from operating heavy or potentially dangerous machinery until events resolve [see Warnings and Precautions (5.1) ]. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Advise patients of the risk of ICANS, to immediately contact their healthcare provider for signs and symptoms associated with ICANS, which may manifest, for example, as confusional state, lethargy, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus, and that the onset of events may be delayed . Advise patients who experience symptoms of ICANS that impair consciousness to refrain from driving or operating heavy or potentially dangerous machinery until symptoms of ICANS resolve [see Warnings and Precautions (5.2) ]. Infections Advise patients of the risk of serious infections, and to contact their healthcare professional for signs or symptoms of serious infection [see Warnings and Precautions (5.3) ]. Cytopenias Discuss the signs and symptoms associated with cytopenias, including neutropenia and febrile neutropenia, anemia, and thrombocytopenia [see Warnings and Precautions (5.4) ] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider if they are pregnant or become pregnant [see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment with EPKINLY and for 4 months after the last dose [see Use in Specific Populations (8.3) ] . Lactation Advise women not to breastfeed during treatment with EPKINLY and for 4 months after the last dose [see Use in Specific Populations (8.2) ] ."],"spl_unclassified_section":["Manufactured by: Genmab US, Inc. Plainsboro, NJ 08536, USA 1-855-4GENMAB (1-855-443-6622) U.S. License Number: 2293 Marketed by: Genmab US, Inc. Plainsboro, NJ 08536 and AbbVie Inc. North Chicago, IL 60064 EPKINLY is a registered trademark owned by Genmab A/S ©2026 Genmab A/S"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For subcutaneous injection only. ( 2.2 ) Recommended Dosage: ( 2.2 ) DLBCL and High-grade B-cell Lymphoma Cycle Cycle = 28 days Day Dose of EPKINLY Cycle 1 1 Step-up dose 1 0.16 mg 8 Step-up dose 2 0.8 mg 15 First full dose 48 mg 22 48 mg Cycles 2 and 3 1, 8, 15 and 22 48 mg Cycles 4 to 9 1 and 15 48 mg Cycle 10 and beyond 1 48 mg EPKINLY as Monotherapy for FL Cycle Cycle = 28 days Day Dose of EPKINLY Cycle 1 1 Step-up dose 1 0.16 mg 8 Step-up dose 2 0.8 mg 15 Step-up dose 3 3 mg 22 First full dose 48 mg Cycles 2 and 3 1, 8, 15 and 22 48 mg Cycles 4 to 9 1 and 15 48 mg Cycle 10 and beyond 1 48 mg EPKINLY in Combination with Lenalidomide and Rituximab for FL Cycle Cycle = 28 days Day Dose of EPKINLY Cycle 1 1 Step-up dose 1 0.16 mg 8 Step-up dose 2 0.8 mg 15 Step-up dose 3 3 mg 22 First full dose 48 mg Cycles 2 and 3 1, 8, 15, and 22 48 mg Cycles 4 to 12 1 48 mg Monitor all patients for signs and symptoms of CRS and ICANS. ( 2.1 ) For patients with DLBCL or high-grade B-cell lymphoma, assess whether hospitalization or outpatient monitoring is appropriate after administration of the Cycle 1 Day 15 dosage of 48 mg. ( 2.1 ) For patients with FL, assess whether hospitalization or outpatient monitoring is appropriate after administration of the Cycle 1 Day 22 dosage of 48 mg. ( 2.1 ) Administer premedications, post-medications, and prophylaxis as recommended. ( 2.4 , 2.5 ) Dosages of EPKINLY 0.16 mg and 0.8 mg require dilution prior to administration. ( 2.7 , 2.8 ) See Full Prescribing Information for instructions on preparation and administration. ( 2.7 , 2.8 , 2.9 , 2.10 ) 2.1 Important Dosing Information Certain doses of EPKINLY require dilution prior to administration. There are 2 available methods to prepare diluted EPKINLY: Empty sterile vial method as described in subsection 2.7 [see Dosage and Administration (2.7) ] , or Sterile syringe method as described in subsection 2.8 [see Dosage and Administration (2.8) ] . Preparation of 3 mg and 48 mg EPKINLY doses does not require dilution. [see Dosage and Administration (2.9) ] . EPKINLY should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as CRS and ICANS [see Warnings and Precautions (5.1 , 5.2) ] . Administer EPKINLY to well-hydrated patients. Premedicate before each dose in Cycle 1 [see Dosage and Administration (2.4) ] . Administer EPKINLY subcutaneously according to the recommended step-up dosage schedule to reduce the incidence and severity of CRS [see Dosage and Administration (2.2) ] . Due to the risk of CRS and ICANS, monitor all patients for signs and symptoms [see Dosage and Administration (2.6) ] . Assess whether hospitalization or outpatient monitoring is appropriate based on comorbidities or other situational factors for the first 48 mg dosage of EPKINLY for patients with: DLBCL or high-grade B-cell lymphoma: on Cycle 1 Day 15 [see Dosage and Administration (2.2) ]. FL: on Cycle 1 Day 22 [see Dosage and Administration (2.2) ]. 2.2 Recommended Dosage EPKINLY is for subcutaneous injection only. The recommended DLBCL dosage for Cycle 1 consists of 2 step-up doses, and the recommended FL dosage (monotherapy or in combination with lenalidomide and rituximab) consists of 3 step-up doses. EPKINLY as Monotherapy: Administer EPKINLY in 28-day cycles until disease progression or unacceptable toxicity. Table 1: EPKINLY Dosage Schedule for Patients with DLBCL or High-grade B-cell Lymphoma Indication Cycle Cycle = 28 days. Day Dose of EPKINLY DLBCL or High-grade B-cell Lymphoma Cycle 1 1 Step-up dose 1 0.16 mg 8 Step-up dose 2 0.8 mg 15 First full dose 48 mg 22 48 mg Cycles 2 and 3 1, 8, 15 and 22 48 mg Cycles 4 to 9 1 and 15 48 mg Cycle 10 and beyond 1 48 mg Table 2: EPKINLY Dosage Schedule for Patients with FL when Given as Monotherapy Indication Cycle Cycle = 28 days. Day Dose of EPKINLY Follicular Lymphoma Cycle 1 1 Step-up dose 1 0.16 mg 8 Step-up dose 2 0.8 mg 15 Step-up dose 3 3 mg 22 First full dose 48 mg Cycles 2 and 3 1, 8, 15 and 22 48 mg Cycles 4 to 9 1 and 15 48 mg Cycle 10 and beyond 1 48 mg EPKINLY in Combination with Lenalidomide and Rituximab: Administer EPKINLY in 28-day cycles for a total of 12 cycles or until disease progression or unacceptable toxicity, whichever occurs first. Table 3: EPKINLY Dosage Schedule in Combination with Lenalidomide and Rituximab for Patients with FL Indication Cycle Cycle = 28 days. Day Dose of EPKINLY Follicular Lymphoma Cycle 1 1 Step-up dose 1 0.16 mg 8 Step-up dose 2 0.8 mg 15 Step-up dose 3 3 mg 22 First full dose 48 mg Cycles 2 and 3 1, 8, 15, and 22 48 mg Cycles 4 to 12 1 48 mg Administer EPKINLY in combination with lenalidomide 20 mg (Days 1 to 21 in Cycles 1 to 12) and rituximab 375 mg/m 2 (Cycles 1 to 5) [see Clinical Studies (14.2) ]. Refer to the lenalidomide prescribing information and rituximab prescribing information for the respective dosage recommendations, including lenalidomide dosage recommendations for patients with renal insufficiency. 2.3 Restarting EPKINLY after Dosage Delay If a dose of EPKINLY is delayed, restart therapy based on the recommendations made in Table 4 for patients with DLBCL or high-grade B-cell lymphoma, or Table 5 for patients with FL [see Dosage and Administration (2.2) ] . Table 4: Recommendations for Restarting EPKINLY After Dosage Delay for Patients with DLBCL or High-grade B-cell Lymphoma Last Dose Administered Time Since the Last Dose Administered Action for Next Dose(s) Administer pretreatment medication prior to EPKINLY dose and monitor patients accordingly [see Dosage and Administration (2.4 , 2.6) ]. 0.16 mg (e.g., on Cycle 1 Day 1) More than 8 days Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. 0.8 mg (e.g., on Cycle 1 Day 8) 14 days or less Administer 48 mg, then resume the planned treatment schedule. More than 14 days Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. 48 mg (e.g., on Cycle 1 Day 15 onwards) 6 weeks or less Administer 48 mg, then resume the planned treatment schedule. More than 6 weeks Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. Table 5: Recommendations for Restarting EPKINLY After Dosage Delay for Patients with FL Last Dose Administered Time Since the Last Dose Administered Action for Next Dose(s) Administer pretreatment medication prior to EPKINLY dose and monitor patients accordingly [see Dosage and Administration (2.4 , 2.6) ]. 0.16 mg (e.g., on Cycle 1 Day 1) More than 8 days Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. 0.8 mg (e.g., on Cycle 1 Day 8) More than 8 days Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. 3 mg (e.g., on Cycle 1 Day 15) 14 days or less Administer 48 mg, then resume the planned treatment schedule. More than 14 days Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. 48 mg (e.g., on Cycle 1 Day 22 onwards) 6 weeks or less Administer 48 mg, then resume the planned treatment schedule. More than 6 weeks Repeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule. 2.4 Recommended Pre- and Post-Administration Medications Administer pre- and post-administration medications as outlined in Table 6 to reduce the risk of CRS [see Warnings and Precautions (5.1) ] . Table 6: EPKINLY Pre- and Post-Administration Medications Cycle Patients requiring medication Medication Administration Cycle 1 All patients Dexamethasone Dexamethasone is the preferred corticosteroid when available. (15 mg oral or intravenous) or Prednisolone (100 mg oral or intravenous) or equivalent 30-120 minutes prior to each weekly administration of EPKINLY And for three consecutive days following each weekly administration of EPKINLY in Cycle 1 Diphenhydramine (50 mg oral or intravenous) or equivalent Acetaminophen (650 mg to 1,000 mg oral) 30-120 minutes prior to each weekly administration of EPKINLY Cycle 2+ Patients who experienced Grade 2 or 3 Patients will be permanently discontinued from EPKINLY after Grade 4 CRS. CRS with previous dose Dexamethasone (15 mg oral or intravenous) or Prednisolone (100 mg oral or intravenous) or equivalent 30-120 minutes prior to next administration of EPKINLY after a Grade 2 or 3 CRS event And for three consecutive days following the next administration of EPKINLY until EPKINLY is given without subsequent CRS of Grade 2 or higher 2.5 Recommended Prophylaxis Pneumocystis jirovecii pneumonia (PJP) Provide PJP prophylaxis during treatment with EPKINLY. Herpesvirus Consider providing prophylaxis against herpesvirus during treatment with EPKINLY to prevent herpes simplex and herpes zoster. Thromboprophylaxis Refer to the lenalidomide prescribing information for recommendations on prophylaxis for venous and arterial thrombotic events. 2.6 Dosage Modifications and Management of Adverse Reactions See Tables 7 and 8 for recommended actions for adverse reactions of CRS and ICANS, respectively. See Tables 9 and 10 for recommended actions for other adverse reactions following administration of EPKINLY given as monotherapy and in combination with lenalidomide and rituximab, respectively. Cytokine Release Syndrome (CRS) Identify CRS based on clinical presentation [see Warnings and Precautions (5.1) ] . Evaluate for and treat other causes of fever, hypotension, and hypoxia. If CRS is suspected, withhold EPKINLY until CRS resolves. Manage according to the recommendations in Table 7 and consider further management per current practice guidelines. Administer supportive therapy for CRS, which may include intensive care for severe or life-threatening CRS. Table 7: Recommendations for Management of Cytokine Release Syndrome Grade Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS. Presenting Symptoms Actions Grade 1 Temperature ≥ 100.4°F (38°C) Premedication may mask fever, therefore if clinical presentation is consistent with CRS, follow these management guidelines. Withhold EPKINLY and manage per current practice guidelines. Ensure CRS symptoms are resolved prior to next dose of EPKINLY. Refer to Table 4 or Table 5 for information on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3) ] . Grade 2 Temperature ≥ 100.4°F (38°C) with: Hypotension not requiring vasopressors and/or Hypoxia requiring low-flow oxygen Low-flow oxygen defined as oxygen delivered at < 6L/minute; high-flow oxygen defined as oxygen delivered at ≥ 6 L/minute. by nasal cannula or blow-by. Withhold EPKINLY and manage per current practice guidelines. Ensure CRS symptoms are resolved prior to next dose of EPKINLY. Administer premedication If Grade 2 or 3 CRS occurs with the second full dose (48 mg) or beyond, administer CRS pre- and post-administration medications with each subsequent dose until a EPKINLY dose is given without subsequent CRS of Grade 2 or higher. Refer to Table 6 for additional information on pre- and post-administration medications. prior to next dose of EPKINLY. For the next dose of EPKINLY, monitor more frequently and consider hospitalization. Grade 3 Temperature ≥ 100.4°F (38°C) with: Hypotension requiring a vasopressor (with or without vasopressin) and/or Hypoxia requiring high-flow oxygen by nasal cannula, face mask, non-rebreather mask, or Venturi mask. Withhold EPKINLY and manage per current practice guidelines, which may include intensive care. Ensure CRS symptoms are resolved prior to the next dose of EPKINLY. Administer premedication prior to next dose of EPKINLY. Hospitalize for the next dose of EPKINLY. Recurrent Grade 3 CRS Permanently discontinue EPKINLY. Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care. Grade 4 Temperature ≥ 100.4°F (38°C) with: Hypotension requiring multiple vasopressors (excluding vasopressin) and/or Hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation). Permanently discontinue EPKINLY. Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care. Immune Effector Cell-Associated Neurological Toxicity Syndrome (ICANS) Monitor patients for signs and symptoms of ICANS [see Warnings and Precautions (5.2) ] . At the first sign of ICANS, withhold EPKINLY and consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care, for ICANS [see Warnings and Precautions (5.2) ]. Manage ICANS according to the recommendations in Table 8 and consider further management per current practice guidelines. Table 8: Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome Grade Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS. Presenting Symptoms Management is determined by the most severe event, not attributable to any other cause. Actions Grade 1 ICE score 7-9 If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (names 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., \"show me 2 fingers\" or \"close your eyes and stick out your tongue\" = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points. , Or depressed level of consciousness Not attributable to any other cause. : awakens spontaneously. Withhold EPKINLY until ICANS resolves. See Table 4 or Table 5 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3) ]. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. Grade 2 ICE score 3-6 , Or depressed level of consciousness : awakens to voice. Withhold EPKINLY until ICANS resolves. Administer dexamethasone All references to dexamethasone administration are dexamethasone or equivalent. 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. Grade 3 ICE score 0-2 , Or depressed level of consciousness : awakens only to tactile stimulus, Or seizures, either: Any clinical seizure, focal or generalized, that resolves rapidly, or Non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, Or raised intracranial pressure: focal/local edema on neuroimaging. First Occurrence of Grade 3 ICANS Withhold EPKINLY until ICANS resolves. Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. Provide supportive therapy, which may include intensive care. Recurrent Grade 3 ICANS Permanently discontinue EPKINLY Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. Provide supportive therapy, which may include intensive care. Grade 4 ICE score 0 , Or depressed level of consciousness : either: Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or Stupor or coma Or seizures, either: Life-threatening prolonged seizure (> 5 minutes), or Repetitive clinical or electrical seizures without return to baseline in between, Or motor findings : Deep focal motor weakness, such as hemiparesis or paraparesis, or raised intracranial pressure/cerebral edema, with signs/symptoms such as: Diffuse cerebral edema on neuroimaging, or Decerebrate or decorticate posturing, or Cranial nerve VI palsy, or Papilledema, or Cushing's triad. Permanently discontinue EPKINLY. Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. Alternatively, consider administration of methylprednisolone 1,000 mg per day intravenously and continue methylprednisolone 1,000 mg per day intravenously for 2 or more days. Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis. Provide supportive therapy, which may include intensive care. Table 9: Recommended Dosage Modifications for Other Adverse Reactions when EPKINLY is Given as Monotherapy Adverse Reaction Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0. Severity Action Infections [see Warnings and Precautions (5.3) ] Grades 1-4 Withhold EPKINLY in patients with active infection, until the infection resolves. See Table 4 or Table 5 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3) ]. For Grade 4, consider permanent discontinuation of EPKINLY. Neutropenia [see Warnings and Precautions (5.4) ] Absolute neutrophil count less than 0.5 × 10 9 /L Withhold EPKINLY until absolute neutrophil count is 0.5 × 10 9 /L or higher. Thrombocytopenia [see Warnings and Precautions (5.4) ] Platelet count less than 50 × 10 9 /L Withhold EPKINLY until platelet count is 50 × 10 9 /L or higher. Other Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 or higher Withhold EPKINLY until the toxicity resolves to Grade 1 or baseline. Table 10: Recommended Dosage Modifications for Other Adverse Reactions when EPKINLY is Given in Combination with Lenalidomide and Rituximab Adverse Reaction Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0. Action Refer to lenalidomide prescribing information for additional toxicity guidelines. Neutropenia [see Warnings and Precautions (5.4) ] Absolute neutrophil count less than 0.5 × 10 9 /L Consider G-CSF. Withhold EPKINLY until absolute neutrophil count is 1 × 10 9 /L or higher. See Table 4 or 5 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3) ]. Withhold lenalidomide for remainder of cycle. On Day 1 of next cycle, the dose of lenalidomide may be maintained if neutropenia was the only toxicity limiting lenalidomide dosing. Febrile Neutropenia [see Warnings and Precautions (5.4) ] Grade 3 or higher Consider G-CSF. Withhold EPKINLY until fever resolves and absolute neutrophil count is 1 × 10 9 /L or higher. Withhold lenalidomide for remainder of cycle. On Day 1 of next cycle, dose of lenalidomide may be maintained if febrile neutropenia was the only toxicity limiting lenalidomide dosing. Thrombocytopenia [see Warnings and Precautions (5.4) ] Platelet count less than 50 × 10 9 /L Withhold EPKINLY until platelet count is 50 × 10 9 /L or higher. Withhold lenalidomide for remainder of cycle. Decrease lenalidomide dose for next cycle. Other Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 For first episode, withhold EPKINLY until improvement to Grade 2 or less or resolution to baseline. For second episode, permanently discontinue EPKINLY if clinically indicated. Grade 4 Permanently discontinue EPKINLY at discretion of healthcare provider. 2.7 Preparation of Diluted EPKINLY using the Vial Method Read this entire section carefully before preparation of EPKINLY. Certain doses of EPKINLY require dilution prior to administration. Follow the preparation instructions provided below, as improper preparation may lead to improper dose. This section describes preparation of diluted EPKINLY using empty sterile vial method. For preparation using sterile syringe method, see subsection 2.8 [see Dosage and Administration (2.8) ] . EPKINLY is prepared and administered by a healthcare provider as a subcutaneous injection. The administration of EPKINLY takes place over the course of 28-day cycles, following the step-up dosage schedule in Section 2.2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use aseptic technique to prepare EPKINLY. Filtration of the diluted solution is not required. 0.16 mg Dose Preparation Instructions ( 2 dilutions required ) – Empty Sterile Vial Method Use an appropriately sized syringe, vial, and needle for each transfer step. 1. Prepare EPKINLY vial a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator. b. Allow the vial to come to room temperature for no more than 1 hour. c. Gently swirl the EPKINLY vial. DO NOT invert, vortex, or vigorously shake the vial. 2. Perform first dilution a. Label an appropriately sized empty vial as \"Dilution A.\" b. Transfer 0.8 mL of EPKINLY into the Dilution A vial. c. Transfer 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A vial. The initially diluted solution contains 0.8 mg/mL of EPKINLY. d. Gently swirl the Dilution A vial for 30 to 45 seconds. 3. Perform second dilution a. Label an appropriately sized empty vial as \"Dilution B.\" b. Transfer 2 mL of solution from the Dilution A vial into the Dilution B vial. The Dilution A vial is no longer needed. c. Transfer 8 mL of 0.9% Sodium Chloride Injection into the Dilution B vial to make a final concentration of 0.16 mg/mL. d. Gently swirl the Dilution B vial for 30 to 45 seconds. 4. Withdraw dose a. Withdraw 1 mL of the diluted EPKINLY from the Dilution B vial into a syringe. 5. Label syringe a. Label the syringe with the dose strength (0.16 mg) and the time of day. Discard the vial containing unused EPKINLY. 0.8 mg Dose Preparation Instructions ( 1 dilution required ) – Empty Sterile Vial Method Use an appropriately sized syringe, vial, and needle for each transfer step. 1. Prepare EPKINLY vial a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator. b. Allow the vial to come to room temperature for no more than 1 hour. c. Gently swirl the EPKINLY vial. DO NOT invert, vortex, or vigorously shake the vial. 2. Perform dilution a. Label an appropriately sized empty vial as \" Dilution A \". b. Transfer 0.8 mL of EPKINLY into the Dilution A vial. c. Transfer 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A vial to make a final concentration of 0.8 mg/mL. d. Gently swirl the Dilution A vial for 30 to 45 seconds. 3. Withdraw dose a. Withdraw 1 mL of the diluted EPKINLY from the Dilution A vial into a syringe. 4. Label syringe a. Label the syringe with the dose strength (0.8 mg) and the time of day. Discard the vial containing unused EPKINLY. 2.8 Preparation of Diluted EPKINLY using the Syringe Method Read this entire section carefully before preparation of EPKINLY. Certain doses of EPKINLY require dilution prior to administration. Follow the preparation instructions provided below, as improper preparation may lead to improper dose. EPKINLY is prepared and administered by a healthcare provider as a subcutaneous injection. The administration of EPKINLY takes place over the course of 28-day cycles, following the step-up dosage schedule in Section 2.2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use aseptic technique to prepare EPKINLY. Filtration of the diluted solution is not required. 0.16 mg Dose Preparation Instructions ( 2 dilutions required ) – Sterile Syringe Method Use an appropriately sized syringe and needle for each transfer step. 1. Prepare EPKINLY vial a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator. b. Allow the vial to come to room temperature for no more than 1 hour. c. Gently swirl the EPKINLY vial. DO NOT invert, vortex, or vigorously shake the vial. 2. Perform first dilution a. Label an appropriately sized syringe as \"Dilution A.\" b. Withdraw 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A syringe. Include approximately 0.2 mL air in the syringe. c. In a new syringe labeled as \"Syringe 1\" , withdraw 0.8 mL of EPKINLY . d. Connect the two syringes and push the 0.8 mL of EPKINLY into the Dilution A syringe. The initially diluted solution contains 0.8 mg/mL of EPKINLY e. Gently mix by inverting the connected syringes 180 degrees 5 times. f. Disconnect the syringes and discard Syringe 1 . 3. Perform second dilution a. Label an appropriately sized syringe as \"Dilution B.\" b. Withdraw 8 mL of 0.9% Sodium Chloride Injection into the Dilution B syringe. Include approximately 0.2 mL air in the syringe. c. Label another appropriately sized syringe as \"Syringe 2.\" d. Connect Syringe 2 to the Dilution A syringe and transfer 2 mL of solution into Syringe 2 . The Dilution A syringe is no longer needed. e. Connect Syringe 2 to the Dilution B syringe and push the 2 mL of solution into the Dilution B syringe to make a final concentration of 0.16 mg/mL. f. Gently mix by inverting the connected syringes 180 degrees 5 times. g. Disconnect the syringes and discard Syringe 2 . 4. Withdraw dose a. Connect and transfer 1 mL of the diluted EPKINLY from the Dilution B syringe into a new syringe. The Dilution B syringe is no longer needed. 5. Label syringe a. Label the syringe with the dose strength (0.16 mg) and the time of day. Discard the vial containing unused EPKINLY. 0.8 mg Dose Preparation Instructions ( 1 dilution required ) – Sterile Syringe Method Use an appropriately sized syringe and needle for each transfer step. 1. Prepare EPKINLY vial a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator. b. Allow the vial to come to room temperature for no more than 1 hour. c. Gently swirl the EPKINLY vial. DO NOT invert, vortex, or vigorously shake the vial. 2. Perform dilution a. Label an appropriately sized syringe as \"Dilution A.\" b. Withdraw 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A syringe. Include approximately 0.2 mL air in the syringe. c. In a new syringe labeled as \" Syringe 1 \", withdraw 0.8 mL of EPKINLY . d. Connect the two syringes and push the 0.8 mL of EPKINLY into the Dilution A syringe to make a final concentration of 0.8 mg/mL. e. Gently mix by inverting the connected syringes 180 degrees 5 times. f. Disconnect the syringes and discard Syringe 1 . 3. Withdraw dose a. Connect a new syringe to the Dilution A syringe and transfer 1 mL of the diluted EPKINLY into the new syringe. The Dilution A syringe is no longer needed. 4. Label syringe a. Label the syringe with the dose strength (0.8 mg) and the time of day. Discard the vial containing unused EPKINLY. 2.9 Preparation of 3 mg and 48 mg EPKINLY Doses Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use aseptic technique to prepare EPKINLY. 3 mg Dose Preparation Instructions (No dilution required) EPKINLY 3 mg dose is required for patients with FL only [see Dosage and Administration (2.2) ] . 1. Prepare EPKINLY vial a. Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator. b. Allow the vial to come to room temperature for no more than 1 hour. c. Gently swirl the EPKINLY vial. DO NOT invert, vortex, or vigorously shake the vial. 2. Withdraw dose a. Withdraw 0.6 mL of EPKINLY into a syringe. 3. Label syringe a. Label the syringe with the dose strength (3 mg) and the time of day. Discard the vial containing unused EPKINLY. 48 mg Dose Preparation Instructions ( No dilution required ) EPKINLY 48 mg/0.8 mL vial is supplied as ready-to-use solution that does not need dilution prior to administration. 1. Prepare EPKINLY vial a. Retrieve one 48 mg/0.8 mL EPKINLY vial from the refrigerator. b. Allow the vial to come to room temperature for no more than 1 hour. c. Gently swirl the EPKINLY vial. DO NOT invert, vortex, or vigorously shake the vial. 2. Withdraw dose a. Withdraw 0.8 mL of EPKINLY into a syringe. 3. Label syringe a. Label the syringe with the dose strength (48 mg) and the time of day. Discard the vial containing unused EPKINLY. 2.10 Storage and Administration Storage of EPKINLY Solution in the Syringe Use EPKINLY solution in the syringe immediately. If not used immediately, store the solution refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours or at room temperature at 20°C to 25°C (68°F to 77°F) for up to 12 hours. The total storage time from the start of dose preparation to administration should not exceed 24 hours. Protect from direct sunlight. Discard unused EPKINLY solution beyond the allowable storage time. Administration of EPKINLY To minimize injection pain, allow EPKINLY solution to equilibrate to room temperature for no more than 1 hour before administration. Inject the required volume of EPKINLY into the subcutaneous tissue of the lower part of the abdomen (preferred injection site) or the thigh. Change of injection site from the left or right side or vice versa is recommended, especially during the weekly administrations (Cycles 1 to 3). Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard, or not intact."],"spl_product_data_elements":["EPKINLY epcoritamab-bysp epcoritamab epcoritamab acetic acid Sorbitol polysorbate 80 sodium acetate EPKINLY epcoritamab-bysp epcoritamab epcoritamab acetic acid Sorbitol polysorbate 80 sodium acetate"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS EPKINLY is a clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous injection: Injection: 4 mg/0.8 mL in a single-dose vial Injection: 48 mg/0.8 mL in a single-dose vial Injection: 4 mg/0.8 mL in a single-dose vial. ( 3 ) Injection: 48 mg/0.8 mL in a single-dose vial. ( 3 )"],"recent_major_changes_table":["
Indications and Usage (1.2)11/2025
Dosage and Administration (2.1)3/2026
Dosage and Administration (2.2, 2.5, 2.6)11/2025
Warnings and Precautions (5.1)3/2026
Warnings and Precautions (5.2, 5.3, 5.4)11/2025
Warnings and Precautions, Infections (5.3)9/2025
"],"clinical_pharmacology_table":["
Table 17: Exposure Parameters of Epcoritamab-bysp in Subjects with Relapsed or Refractory LBCL or FL Following Recommended Dosage
Cavg (mcg/mL)Values are geometric mean with geometric CV%.Cmax (mcg/mL)Ctrough (mcg/mL)
First full 48 mg doseFirst full 48 mg dose is on the first day of Week 3 in subjects with relapsed or refractory LBCL and on the first day of Week 4 in subjects with relapsed or refractory FL.1.3 (113.3%)1.7 (106.7%)1.4 (100.9%)
End of weekly dosing (end of Cycle 3)9.1 (45.9%)9.9 (43.4%)7.8 (52.4%)
End of every 2-week dosing (end of Cycle 9)5.3 (57%)6.7 (49.4%)3.6 (81.5%)
Steady stateSteady state values are approximated at Cycle 15 (Week 60). with every 4-week dosing2.4 (73.3%)4.2 (59.8%)1.1 (134.1%)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on the mechanism of action, EPKINLY may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of EPKINLY in pregnant women to evaluate for a drug-associated risk. No animal reproductive or developmental toxicity studies have been conducted with epcoritamab-bysp. Epcoritamab-bysp causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD20 on B-cells and the finding of B-cell depletion in non-pregnant animals, epcoritamab-bysp can cause B-cell lymphocytopenia in infants exposed to epcoritamab-bysp in-utero. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, EPKINLY has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary There is no information regarding the presence of epcoritamab-bysp in human milk, the effect on the breastfed child, or milk production. Because maternal IgG is present in human milk, and there is potential for epcoritamab-bysp absorption leading to serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with EPKINLY and for 4 months after the last dose. 8.3 Females and Males of Reproductive Potential EPKINLY may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating EPKINLY. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with EPKINLY and for 4 months after the last dose. 8.4 Pediatric Use The safety and efficacy of EPKINLY in pediatric patients have not been established. 8.5 Geriatric Use LBCL In patients with relapsed or refractory LBCL who received EPKINLY in EPCORE NHL-1, 77 (49%) were 65 years of age and older, and 29 (19%) were 75 years of age or older. No clinically meaningful differences in safety or efficacy were observed between patients with relapsed or refractory LBCL who were 65 years of age and older compared with younger adult patients. FL In patients with relapsed or refractory FL who received EPKINLY in combination with lenalidomide and rituximab in EPCORE FL-1, 88 (36%) were 65 years of age or older and 20 (8%) were 75 years of age or older. No clinically meaningful differences in safety or efficacy were observed between patients who were 65 years of age and older compared with younger patients. In patients with relapsed or refractory FL who received EPKINLY in EPCORE NHL-1, 66 (52%) were 65 years of age or older, and 16 (13%) were 75 years of age and older. In patients with relapsed or refractory FL, there was a higher rate of fatal adverse reactions, primarily infections, including COVID-19, in patients older than 65 years of age compared to younger adult patients. No overall difference in efficacy was observed in patients with relapsed or refractory FL who were 65 years of age and older compared with younger patients."],"dosage_and_administration_table":["
Cycle Cycle = 28 daysDayDose of EPKINLY
Cycle 11Step-up dose 10.16 mg
8Step-up dose 20.8 mg
15First full dose48 mg
2248 mg
Cycles 2 and 31, 8, 15 and 2248 mg
Cycles 4 to 91 and 1548 mg
Cycle 10 and beyond148 mg
","
CycleCycle = 28 daysDayDose of EPKINLY
Cycle 11Step-up dose 10.16 mg
8Step-up dose 20.8 mg
15Step-up dose 33 mg
22First full dose48 mg
Cycles 2 and 31, 8, 15 and 2248 mg
Cycles 4 to 91 and 1548 mg
Cycle 10 and beyond148 mg
","
CycleCycle = 28 daysDayDose of EPKINLY
Cycle 11Step-up dose 10.16 mg
8Step-up dose 20.8 mg
15Step-up dose 33 mg
22First full dose48 mg
Cycles 2 and 31, 8, 15, and 2248 mg
Cycles 4 to 12148 mg
","
Table 1: EPKINLY Dosage Schedule for Patients with DLBCL or High-grade B-cell Lymphoma
IndicationCycleCycle = 28 days.DayDose of EPKINLY
DLBCL or High-grade B-cell LymphomaCycle 11Step-up dose 10.16 mg
8Step-up dose 20.8 mg
15First full dose48 mg
2248 mg
Cycles 2 and 31, 8, 15 and 2248 mg
Cycles 4 to 91 and 1548 mg
Cycle 10 and beyond148 mg
","
Table 2: EPKINLY Dosage Schedule for Patients with FL when Given as Monotherapy
IndicationCycleCycle = 28 days.DayDose of EPKINLY
Follicular LymphomaCycle 11Step-up dose 10.16 mg
8Step-up dose 20.8 mg
15Step-up dose 33 mg
22First full dose48 mg
Cycles 2 and 31, 8, 15 and 2248 mg
Cycles 4 to 91 and 1548 mg
Cycle 10 and beyond148 mg
","
Table 3: EPKINLY Dosage Schedule in Combination with Lenalidomide and Rituximab for Patients with FL
IndicationCycleCycle = 28 days.DayDose of EPKINLY
Follicular LymphomaCycle 11Step-up dose 10.16 mg
8Step-up dose 20.8 mg
15Step-up dose 33 mg
22First full dose48 mg
Cycles 2 and 31, 8, 15, and 2248 mg
Cycles 4 to 12148 mg
","
Table 4: Recommendations for Restarting EPKINLY After Dosage Delay for Patients with DLBCL or High-grade B-cell Lymphoma
Last Dose AdministeredTime Since the Last Dose AdministeredAction for Next Dose(s)Administer pretreatment medication prior to EPKINLY dose and monitor patients accordingly [see Dosage and Administration (2.4, 2.6)].
0.16 mg (e.g., on Cycle 1 Day 1)More than 8 daysRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
0.8 mg (e.g., on Cycle 1 Day 8)14 days or lessAdminister 48 mg, then resume the planned treatment schedule.
More than 14 daysRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
48 mg (e.g., on Cycle 1 Day 15 onwards)6 weeks or lessAdminister 48 mg, then resume the planned treatment schedule.
More than 6 weeksRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
","
Table 5: Recommendations for Restarting EPKINLY After Dosage Delay for Patients with FL
Last Dose AdministeredTime Since the Last Dose AdministeredAction for Next Dose(s)Administer pretreatment medication prior to EPKINLY dose and monitor patients accordingly [see Dosage and Administration (2.4, 2.6)].
0.16 mg (e.g., on Cycle 1 Day 1)More than 8 daysRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
0.8 mg (e.g., on Cycle 1 Day 8)More than 8 daysRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
3 mg (e.g., on Cycle 1 Day 15)14 days or lessAdminister 48 mg, then resume the planned treatment schedule.
More than 14 daysRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
48 mg (e.g., on Cycle 1 Day 22 onwards)6 weeks or lessAdminister 48 mg, then resume the planned treatment schedule.
More than 6 weeksRepeat Cycle 1 schedule starting at step-up dose 1 (0.16 mg). Following the repeat of Cycle 1 schedule, resume the planned treatment schedule.
","
Table 6: EPKINLY Pre- and Post-Administration Medications
CyclePatients requiring medicationMedicationAdministration
Cycle 1All patientsDexamethasoneDexamethasone is the preferred corticosteroid when available. (15 mg oral or intravenous) or Prednisolone (100 mg oral or intravenous) or equivalent30-120 minutes prior to each weekly administration of EPKINLYAnd for three consecutive days following each weekly administration of EPKINLY in Cycle 1
Diphenhydramine (50 mg oral or intravenous) or equivalent Acetaminophen (650 mg to 1,000 mg oral)30-120 minutes prior to each weekly administration of EPKINLY
Cycle 2+Patients who experienced Grade 2 or 3Patients will be permanently discontinued from EPKINLY after Grade 4 CRS. CRS with previous doseDexamethasone (15 mg oral or intravenous) or Prednisolone (100 mg oral or intravenous) or equivalent30-120 minutes prior to next administration of EPKINLY after a Grade 2 or 3 CRS eventAnd for three consecutive days following the next administration of EPKINLY until EPKINLY is given without subsequent CRS of Grade 2 or higher
","
Table 7: Recommendations for Management of Cytokine Release Syndrome
GradeBased on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS.Presenting SymptomsActions
Grade 1Temperature ≥ 100.4°F (38°C)Premedication may mask fever, therefore if clinical presentation is consistent with CRS, follow these management guidelines.Withhold EPKINLY and manage per current practice guidelines.Ensure CRS symptoms are resolved prior to next dose of EPKINLY.Refer to Table 4 or Table 5 for information on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].
Grade 2Temperature ≥ 100.4°F (38°C) with: Hypotension not requiring vasopressors and/or Hypoxia requiring low-flow oxygenLow-flow oxygen defined as oxygen delivered at < 6L/minute; high-flow oxygen defined as oxygen delivered at ≥ 6 L/minute. by nasal cannula or blow-by.Withhold EPKINLY and manage per current practice guidelines.Ensure CRS symptoms are resolved prior to next dose of EPKINLY.Administer premedicationIf Grade 2 or 3 CRS occurs with the second full dose (48 mg) or beyond, administer CRS pre- and post-administration medications with each subsequent dose until a EPKINLY dose is given without subsequent CRS of Grade 2 or higher. Refer to Table 6 for additional information on pre- and post-administration medications. prior to next dose of EPKINLY.For the next dose of EPKINLY, monitor more frequently and consider hospitalization.
Grade 3Temperature ≥ 100.4°F (38°C) with: Hypotension requiring a vasopressor (with or without vasopressin) and/or Hypoxia requiring high-flow oxygen by nasal cannula, face mask, non-rebreather mask, or Venturi mask.Withhold EPKINLY and manage per current practice guidelines, which may include intensive care.Ensure CRS symptoms are resolved prior to the next dose of EPKINLY.Administer premedication prior to next dose of EPKINLY.Hospitalize for the next dose of EPKINLY.
Recurrent Grade 3 CRS Permanently discontinue EPKINLY.Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.
Grade 4Temperature ≥ 100.4°F (38°C) with: Hypotension requiring multiple vasopressors (excluding vasopressin) and/or Hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation).Permanently discontinue EPKINLY.Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.
","
Table 8: Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome
GradeBased on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS.Presenting SymptomsManagement is determined by the most severe event, not attributable to any other cause.Actions
Grade 1ICE score 7-9If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (names 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., "show me 2 fingers" or "close your eyes and stick out your tongue" = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points., Or depressed level of consciousnessNot attributable to any other cause.: awakens spontaneously.Withhold EPKINLY until ICANS resolves.See Table 4 or Table 5 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.
Grade 2ICE score 3-6, Or depressed level of consciousness: awakens to voice.Withhold EPKINLY until ICANS resolves.Administer dexamethasoneAll references to dexamethasone administration are dexamethasone or equivalent. 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.
Grade 3ICE score 0-2, Or depressed level of consciousness: awakens only to tactile stimulus, Or seizures, either: Any clinical seizure, focal or generalized, that resolves rapidly, orNon-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, Or raised intracranial pressure: focal/local edema on neuroimaging.First Occurrence of Grade 3 ICANS Withhold EPKINLY until ICANS resolves.Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.Provide supportive therapy, which may include intensive care.
Recurrent Grade 3 ICANS Permanently discontinue EPKINLYAdminister dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.Provide supportive therapy, which may include intensive care.
Grade 4ICE score 0, Or depressed level of consciousness: either: Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, orStupor or coma Or seizures, either: Life-threatening prolonged seizure (> 5 minutes), orRepetitive clinical or electrical seizures without return to baseline in between, Or motor findings: Deep focal motor weakness, such as hemiparesis or paraparesis, or raised intracranial pressure/cerebral edema, with signs/symptoms such as: Diffuse cerebral edema on neuroimaging, orDecerebrate or decorticate posturing, orCranial nerve VI palsy, orPapilledema, orCushing's triad.Permanently discontinue EPKINLY.Administer dexamethasone 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.Alternatively, consider administration of methylprednisolone 1,000 mg per day intravenously and continue methylprednisolone 1,000 mg per day intravenously for 2 or more days.Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management, including consideration for starting non-sedating, anti-seizure medicines for seizure prophylaxis.Provide supportive therapy, which may include intensive care.
","
Table 9: Recommended Dosage Modifications for Other Adverse Reactions when EPKINLY is Given as Monotherapy
Adverse ReactionBased on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.SeverityAction
Infections [see Warnings and Precautions (5.3)]Grades 1-4Withhold EPKINLY in patients with active infection, until the infection resolves.See Table 4 or Table 5 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].For Grade 4, consider permanent discontinuation of EPKINLY.
Neutropenia [see Warnings and Precautions (5.4)]Absolute neutrophil count less than 0.5 × 109/LWithhold EPKINLY until absolute neutrophil count is 0.5 × 109/L or higher.
Thrombocytopenia [see Warnings and Precautions (5.4)]Platelet count less than 50 × 109/LWithhold EPKINLY until platelet count is 50 × 109/L or higher.
Other Adverse Reactions [see Adverse Reactions (6.1)]Grade 3 or higherWithhold EPKINLY until the toxicity resolves to Grade 1 or baseline.
","
Table 10: Recommended Dosage Modifications for Other Adverse Reactions when EPKINLY is Given in Combination with Lenalidomide and Rituximab
Adverse ReactionSeverityBased on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.ActionRefer to lenalidomide prescribing information for additional toxicity guidelines.
Neutropenia [see Warnings and Precautions (5.4)]Absolute neutrophil count less than 0.5 × 109/LConsider G-CSF.Withhold EPKINLY until absolute neutrophil count is 1 × 109/L or higher.See Table 4 or 5 for recommendations on restarting EPKINLY after dosage delays [see Dosage and Administration (2.3)].Withhold lenalidomide for remainder of cycle. On Day 1 of next cycle, the dose of lenalidomide may be maintained if neutropenia was the only toxicity limiting lenalidomide dosing.
Febrile Neutropenia [see Warnings and Precautions (5.4)]Grade 3 or higherConsider G-CSF.Withhold EPKINLY until fever resolves and absolute neutrophil count is 1 × 109/L or higher.Withhold lenalidomide for remainder of cycle. On Day 1 of next cycle, dose of lenalidomide may be maintained if febrile neutropenia was the only toxicity limiting lenalidomide dosing.
Thrombocytopenia [see Warnings and Precautions (5.4)]Platelet count less than 50 × 109/LWithhold EPKINLY until platelet count is 50 × 109/L or higher.Withhold lenalidomide for remainder of cycle. Decrease lenalidomide dose for next cycle.
Other Adverse Reactions [see Adverse Reactions (6.1)]Grade 3For first episode, withhold EPKINLY until improvement to Grade 2 or less or resolution to baseline.For second episode, permanently discontinue EPKINLY if clinically indicated.
Grade 4Permanently discontinue EPKINLY at discretion of healthcare provider.
","Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.Allow the vial to come to room temperature for no more than 1 hour.Gently swirl the EPKINLY vial.DO NOT invert, vortex, or vigorously shake the vial.Label an appropriately sized empty vial as "Dilution A."Transfer 0.8 mL of EPKINLY into the Dilution A vial.Transfer 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A vial. The initially diluted solution contains 0.8 mg/mL of EPKINLY.Gently swirl the Dilution A vial for 30 to 45 seconds.Label an appropriately sized empty vial as "Dilution B."Transfer 2 mL of solution from the Dilution A vial into the Dilution B vial. The Dilution A vial is no longer needed.Transfer 8 mL of 0.9% Sodium Chloride Injection into the Dilution B vial to make a final concentration of 0.16 mg/mL.Gently swirl the Dilution B vial for 30 to 45 seconds.Withdraw 1 mL of the diluted EPKINLY from the Dilution B vial into a syringe.Label the syringe with the dose strength (0.16 mg) and the time of day.
1. Prepare EPKINLY vial
a.b.c.
2. Perform first dilution
a.b.c.d.
3. Perform second dilution
a.b.c.d.
4. Withdraw dose
a.
5. Label syringe
a.
","Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.Allow the vial to come to room temperature for no more than 1 hour.Gently swirl the EPKINLY vial.DO NOT invert, vortex, or vigorously shake the vial.Label an appropriately sized empty vial as "Dilution A". Transfer 0.8 mL of EPKINLY into the Dilution A vial.Transfer 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A vial to make a final concentration of 0.8 mg/mL.Gently swirl the Dilution A vial for 30 to 45 seconds.Withdraw 1 mL of the diluted EPKINLY from the Dilution A vial into a syringe.Label the syringe with the dose strength (0.8 mg) and the time of day.
1. Prepare EPKINLY vial
a.b.c.
2. Perform dilution
a.b.c.d.
3. Withdraw dose
a.
4. Label syringe
a.
","Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.Allow the vial to come to room temperature for no more than 1 hour.Gently swirl the EPKINLY vial.DO NOT invert, vortex, or vigorously shake the vial.Label an appropriately sized syringe as "Dilution A."Withdraw 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A syringe. Include approximately 0.2 mL air in the syringe.In a new syringe labeled as "Syringe 1", withdraw 0.8 mL of EPKINLY.Connect the two syringes and push the 0.8 mL of EPKINLY into the Dilution A syringe. The initially diluted solution contains 0.8 mg/mL of EPKINLYGently mix by inverting the connected syringes 180 degrees 5 times.Disconnect the syringes and discard Syringe 1.Label an appropriately sized syringe as "Dilution B."Withdraw 8 mL of 0.9% Sodium Chloride Injection into the Dilution B syringe. Include approximately 0.2 mL air in the syringe.Label another appropriately sized syringe as "Syringe 2."Connect Syringe 2 to the Dilution A syringe and transfer 2 mL of solution into Syringe 2. The Dilution A syringe is no longer needed.Connect Syringe 2 to the Dilution B syringe and push the 2 mL of solution into the Dilution B syringe to make a final concentration of 0.16 mg/mL.Gently mix by inverting the connected syringes 180 degrees 5 times.Disconnect the syringes and discard Syringe 2.Connect and transfer 1 mL of the diluted EPKINLY from the Dilution B syringe into a new syringe. The Dilution B syringe is no longer needed.Label the syringe with the dose strength (0.16 mg) and the time of day.
1. Prepare EPKINLY vial
a.b.c.
2. Perform first dilution
a.b.c.d.e.f.
3. Perform second dilution
a.b.c.d.e.f.g.
4. Withdraw dose
a.
5. Label syringe
a.
","Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.Allow the vial to come to room temperature for no more than 1 hour.Gently swirl the EPKINLY vial.DO NOT invert, vortex, or vigorously shake the vial.Label an appropriately sized syringe as "Dilution A."Withdraw 4.2 mL of 0.9% Sodium Chloride Injection into the Dilution A syringe. Include approximately 0.2 mL air in the syringe.In a new syringe labeled as "Syringe 1", withdraw 0.8 mL of EPKINLY.Connect the two syringes and push the 0.8 mL of EPKINLY into the Dilution A syringe to make a final concentration of 0.8 mg/mL.Gently mix by inverting the connected syringes 180 degrees 5 times.Disconnect the syringes and discard Syringe 1.Connect a new syringe to the Dilution A syringe and transfer 1 mL of the diluted EPKINLY into the new syringe. The Dilution A syringe is no longer needed.Label the syringe with the dose strength (0.8 mg) and the time of day.
1. Prepare EPKINLY vial
a.b.c.
2. Perform dilution
a.b.c.d.e.f.
3. Withdraw dose
a.
4. Label syringe
a.
","Retrieve one 4 mg/0.8 mL EPKINLY vial from the refrigerator.Allow the vial to come to room temperature for no more than 1 hour. Gently swirl the EPKINLY vial.Withdraw 0.6 mL of EPKINLY into a syringe.Label the syringe with the dose strength (3 mg) and the time of day.
1. Prepare EPKINLY vial
a.b.c.
DO NOT invert, vortex, or vigorously shake the vial.
2. Withdraw dose
a.
3. Label syringe
a.
","Retrieve one 48 mg/0.8 mL EPKINLY vial from the refrigerator.Allow the vial to come to room temperature for no more than 1 hour. Gently swirl the EPKINLY vial.Withdraw 0.8 mL of EPKINLY into a syringe.Label the syringe with the dose strength (48 mg) and the time of day.
1. Prepare EPKINLY vial
a.b.c.
DO NOT invert, vortex, or vigorously shake the vial.
2. Withdraw dose
a.
3. Label syringe
a.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 48 mg/0.8 mL Vial Carton NDC 82705-010-01 Rx only epkinly ® (epcoritamab-bysp) Injection 48 mg/0.8 mL For subcutaneous injection by a healthcare provider only. Provide enclosed Medication Guide to patient. One single-dose vial. Discard unused portion. Genmab abbvie PRINCIPAL DISPLAY PANEL - 48 mg/0.8 mL Vial Carton","PRINCIPAL DISPLAY PANEL - 4 mg/0.8 mL Vial Carton NDC 82705-002-01 Rx only epkinly ® (epcoritamab-bysp) Injection 4 mg/0.8 mL For subcutaneous injection by a healthcare provider only. Provide enclosed Medication Guide to patient. One single-dose vial. Discard unused portion. Genmab abbvie PRINCIPAL DISPLAY PANEL - 4 mg/0.8 mL Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity or genotoxicity studies have been conducted with epcoritamab-bysp. No dedicated studies have been conducted to evaluate the effects of epcoritamab-bysp on fertility."]},"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"T-cell surface glycoprotein CD3","category":"target"},{"label":"CD3D","category":"gene"},{"label":"CD3E","category":"gene"},{"label":"CD3G","category":"gene"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Relapsed or refractory diffuse large B-cell lymphoma","category":"indication"},{"label":"Genmab Us, Inc.","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.1) ] . Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE SYNDROME and IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME See full prescribing information for complete boxed warning. Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.1 ) Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.6 , 5.2 )"],"safetySignals":[{"date":"","signal":"CYTOKINE RELEASE SYNDROME","source":"FDA FAERS","actionTaken":"392 reports"},{"date":"","signal":"DIFFUSE LARGE B-CELL LYMPHOMA","source":"FDA FAERS","actionTaken":"219 reports"},{"date":"","signal":"DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY","source":"FDA FAERS","actionTaken":"208 reports"},{"date":"","signal":"IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"80 reports"},{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"NEUTROPHIL COUNT DECREASED","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"HYPOGAMMAGLOBULINAEMIA","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"PLATELET COUNT DECREASED","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"CYTOMEGALOVIRUS INFECTION REACTIVATION","source":"FDA FAERS","actionTaken":"33 reports"}],"commonSideEffects":[{"effect":"Cytokine release syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Fatigue","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Injection site reactions","drugRate":"≥ 27%","severity":"serious","_validated":true},{"effect":"Musculoskeletal pain","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Pyrexia","drugRate":"≥ 24%","severity":"serious","_validated":true},{"effect":"Abdominal pain","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"≥ 20%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Decreased lymphocyte count","drugRate":"≥ 10%","severity":"common","_validated":true},{"effect":"Decreased neutrophil count","drugRate":"≥ 10%","severity":"common","_validated":true},{"effect":"Decreased white blood cell count","drugRate":"≥ 10%","severity":"common","_validated":true},{"effect":"Decreased hemoglobin","drugRate":"≥ 10%","severity":"common","_validated":true},{"effect":"Decreased platelets","drugRate":"≥ 10%","severity":"common","_validated":true},{"effect":"Edema","drugRate":"≥ 14.1%","severity":"common","_validated":true},{"effect":"Rash","drugRate":"≥ 15%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"≥ 13%","severity":"common","_validated":true},{"effect":"Cardiac arrhythmias","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Decreased appetite","drugRate":"≥ 12%","severity":"common","_validated":true},{"effect":"ICANS","drugRate":"reported","severity":"unknown"},{"effect":"Sepsis","drugRate":"reported","severity":"unknown"},{"effect":"Pleural effusion","drugRate":"reported","severity":"unknown"},{"effect":"COVID-19","drugRate":"reported","severity":"unknown"},{"effect":"Pneumonia","drugRate":"reported","severity":"unknown"},{"effect":"Tumor flare","drugRate":"reported","severity":"unknown"},{"effect":"Febrile neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Upper respiratory tract infections","drugRate":"reported","severity":"unknown"},{"effect":"Tumor lysis syndrome","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Based on the mechanism of action, EPKINLY may cause fetal harm when administered to pregnant woman. There are no available data on the use of EPKINLY in pregnant women to evaluate for drug-associated risk. No animal reproductive or developmental toxicity studies have been conducted with epcoritamab-bysp. Epcoritamab-bysp causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD20 on B-cells and the finding of B-cell depletion in non-pregnant animals, epcoritamab-bysp can cause B-cell lymphocytopenia in infants exposed to epcoritamab-bysp in-utero. Human immunoglobulin (IgG) is known to cross the placenta; therefore, EPKINLY has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"In patients with relapsed or refractory LBCL who received EPKINLY in the clinical trial, 49% were 65 years of age or older, and 19% were 75 years of age or older. No clinically meaningful differences in safety or efficacy were observed between patients 65 years of age or older compared with younger adult patients.","Paediatric use":"The safety and efficacy of EPKINLY in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Genmab Us, Inc.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPCORITAMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:21:55.788514+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Epcoritamab","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:22:04.161964+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:22:02.778882+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:21:52.923246+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPCORITAMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:22:03.584265+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:51.888945+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:51.889001+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.1) ] . Immune Effector Cell","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:51.889025+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:22:05.059629+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: T cell surface glycoprotein CD3 binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:22:04.161652+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650393/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:22:04.057586+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761324","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:51.889039+00:00"}},"allNames":"epkinly","offLabel":[],"synonyms":["epcoritamab","epcoritamab-bysp","GEN3013","epkinly"],"timeline":[{"date":"2023-05-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Genmab Us, Inc.)"}],"approvals":[{"date":"2023-05-19","orphan":false,"company":"GENMAB US, INC.","regulator":"FDA"}],"brandName":"Epkinly","ecosystem":[{"indication":"Relapsed or refractory diffuse large B-cell lymphoma","otherDrugs":[{"name":"glofitamab","slug":"glofitamab","company":"Genentech Inc"}],"globalPrevalence":null}],"mechanism":{"target":"T-cell surface glycoprotein CD3","novelty":"Follow-on","targets":[{"gene":"CD3D","source":"DrugCentral","target":"T-cell surface glycoprotein CD3","protein":"T-cell surface glycoprotein CD3 delta chain"},{"gene":"CD3E","source":"DrugCentral","target":"T-cell surface glycoprotein CD3","protein":"T-cell surface glycoprotein CD3 epsilon chain"},{"gene":"CD3G","source":"DrugCentral","target":"T-cell surface glycoprotein CD3","protein":"T-cell surface glycoprotein CD3 gamma chain"},{"gene":"MS4A1","source":"DrugCentral","target":"B-lymphocyte antigen CD20","protein":"B-lymphocyte antigen CD20"}],"modality":"Monoclonal Antibody","drugClass":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","explanation":"Epcoritamab-bysp is T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells.In vitro, epcoritamab-bysp activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells.","oneSentence":"Epkinly works by binding to the T-cell surface glycoprotein CD3, which is a key component of the T-cell receptor complex.","technicalDetail":"Epkinly is a monoclonal antibody that binds to the epsilon chain of the T-cell surface glycoprotein CD3, a component of the T-cell receptor complex, thereby inhibiting T-cell activation and proliferation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Epcoritamab","title":"Epcoritamab","extract":"Epcoritamab, sold under the brand name Epkinly, is a Bi-specific T-cell engager (BiTE) used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab.","wiki_history":"== History ==\nEpcoritamab was evaluated in the EPCORE NHL-1 (NCT03625037) trial in 148 participants with relapsed or refractory B-cell lymphoma after two or more lines of systemic therapy, including at least one anti-CD20 monoclonal antibody-containing therapy.\n\nFor the treatement of follicular lymphoma, the efficacy and safety were evaluated in EPCORE NHL-1 (Study GCT3013-01; NCT03625037), an open-label, multi-cohort, multicenter, single-arm trial that included 127 participants with relapsed or refractory FL after at least two lines of systemic therapy. The primary efficacy and safety were based on 127 participants who received a two step-up dosing regimen. A separate dose optimization cohort of 86 participants evaluated the recommended 3-step up dosage schedule for cytokine release syndrome mitigation.\n\nThe US Food and Drug Administration (FDA) granted the application for epcoritamab for follicular lymphoma priority review and breakthrough therapy designations.\n\nApproval of epcoritamab with lenalidomide and rituximab was based on EPCORE FL-1 (study M20-638; NCT05409066), a randomized, open-label trial that enrolled 488 participants with relapsed or refractory FL. Participants were randomized (1:1) to receive epcoritamab-bysp plus R2 or R2 alone. Participants had a median of one prior line of systemic therapy (range: 1 to 7); 24% and 17% had two and three or more prior lines, respectively.","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nIn July 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended a conditional marketing authorization for epcoritamab (Tepkinly). It was approved for medical use in the European Union in September 2023. The EMA granted orphan drug designation to epcoritamab in both February and June 2022.\n\n=== Names ===\nEpcoritamab is the international nonproprietary name."},"commercial":{"launchDate":"2023","_launchSource":"DrugCentral (FDA 2023-05-19, GENMAB US, INC.)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5734","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPCORITAMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPCORITAMAB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Epcoritamab","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:01:54.577571","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:22:09.942762+00:00","fieldsConflicting":6,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"blinatumomab","drugSlug":"blinatumomab","fdaApproval":"2014-12-03","relationship":"same-target"},{"drugName":"muromonab-CD3","drugSlug":"muromonab-cd3","fdaApproval":"1992-09-14","relationship":"same-target"},{"drugName":"talquetamab","drugSlug":"talquetamab","fdaApproval":"2023-08-09","relationship":"same-target"},{"drugName":"tebentafusp","drugSlug":"tebentafusp","fdaApproval":"2022-01-25","relationship":"same-target"},{"drugName":"teclistamab","drugSlug":"teclistamab","fdaApproval":"2022-10-25","relationship":"same-target"},{"drugName":"teplizumab","drugSlug":"teplizumab","fdaApproval":"2022-11-17","relationship":"same-target"}],"genericName":"epcoritamab","indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma","source":"DrugCentral","snomedId":1172695008,"regulator":"FDA","eligibility":{"who can take it":{"age":"adult patients","type":"DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma","stage":"relapsed or refractory","prior treatment":"two or more lines of systemic therapy"}}}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"blinatumomab","brandName":"blinatumomab","genericName":"blinatumomab","approvalYear":"2014","relationship":"same-target"},{"drugId":"muromonab-cd3","brandName":"muromonab-CD3","genericName":"muromonab-CD3","approvalYear":"1992","relationship":"same-target"},{"drugId":"talquetamab","brandName":"talquetamab","genericName":"talquetamab","approvalYear":"2023","relationship":"same-target"},{"drugId":"tebentafusp","brandName":"tebentafusp","genericName":"tebentafusp","approvalYear":"2022","relationship":"same-target"},{"drugId":"teclistamab","brandName":"teclistamab","genericName":"teclistamab","approvalYear":"2022","relationship":"same-target"},{"drugId":"teplizumab","brandName":"teplizumab","genericName":"teplizumab","approvalYear":"2022","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06931652","phase":"PHASE2","title":"Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2025-09-22","conditions":["Primary CNS Lymphoma (PCNSL)"],"enrollment":60,"completionDate":"2030-01"},{"nctId":"NCT06510361","phase":"PHASE2","title":"Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-11-20","conditions":["Lymphoma","Follicular Lymphoma","Lymphoma,Non-Hodgkin","Lymphoma, Non-Hodgkin's, Adult"],"enrollment":35,"completionDate":"2028-05-01"},{"nctId":"NCT07218510","phase":"PHASE2","title":"Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-07","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":33,"completionDate":"2029-06-08"},{"nctId":"NCT06510491","phase":"PHASE2","title":"Epcoritamab in Previously Treated WM","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2024-12-06","conditions":["Waldenstrom Macroglobulinemia","B-Cell Lymphoproliferative Disorder"],"enrollment":20,"completionDate":"2027-12-31"},{"nctId":"NCT07030699","phase":"PHASE2","title":"A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-13","conditions":["Lymphoma"],"enrollment":27,"completionDate":"2028-08"},{"nctId":"NCT07451652","phase":"PHASE2","title":"Low Dose Epcoritamab Plus GemOx in R/R DLBCL","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-02","conditions":["Relapsed/Refractory Diffuse Large B Cell Lymphoma"],"enrollment":10,"completionDate":"2027-09"},{"nctId":"NCT04623541","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":["Relapsed/Refractory Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Richter's Syndrome","Treatment-naïve High Risk Chronic Lymphocytic Leukemia"],"enrollment":195,"completionDate":"2028-02"},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":["Non-Hodgkin Lymphoma"],"enrollment":496,"completionDate":"2032-11"},{"nctId":"NCT03625037","phase":"PHASE1,PHASE2","title":"First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","isPivotal":true,"startDate":"2018-06-26","conditions":["DLBCL","High-grade B-cell Lymphoma (HGBCL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","FL","MCL","Small Lymphocytic Lymphoma (SLL)","Marginal Zone Lymphoma (MZL)","Indolent B-cell Non-Hodgkin Lymphoma (iNHL)","Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)"],"enrollment":666,"completionDate":"2029-01"},{"nctId":"NCT04663347","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"enrollment":543,"completionDate":"2027-09-30"},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":["Follicular Lymphoma (FL)"],"enrollment":1095,"completionDate":"2037-11"},{"nctId":"NCT05660967","phase":"PHASE2","title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-03-06","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":111,"completionDate":"2026-06-28"},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":360,"completionDate":"2028-01"},{"nctId":"NCT04542824","phase":"PHASE1,PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":["Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Primary Mediastinal Large B Cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma"],"enrollment":78,"completionDate":"2027-09"},{"nctId":"NCT04628494","phase":"PHASE3","title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2021-01-13","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":484,"completionDate":"2028-04"},{"nctId":"NCT07226752","phase":"PHASE3","title":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-10-08","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":72,"completionDate":"2028-06-14"},{"nctId":"NCT06919939","phase":"PHASE2","title":"Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2026-01-07","conditions":["Large B-cell Lymphoma","Relapse"],"enrollment":26,"completionDate":"2031-01-07"},{"nctId":"NCT06045247","phase":"PHASE2","title":"Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-05","conditions":["Large B-cell Lymphoma"],"enrollment":40,"completionDate":"2030-07-31"},{"nctId":"NCT07283679","phase":"PHASE1,PHASE2","title":"Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-01","conditions":["Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B-cell Non-Hodgkin Lymphoma"],"enrollment":30,"completionDate":"2033-09-30"},{"nctId":"NCT06811272","phase":"PHASE2","title":"Outpatient Epcoritamab as 2L in NTE R/R DLBCL","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-06-05","conditions":["Relapsed Large B-cell Lymphoma","Refractory Large B-cell Lymphoma"],"enrollment":30,"completionDate":"2028-10-01"},{"nctId":"NCT06536049","phase":"PHASE1,PHASE2","title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Yazeed Sawalha","startDate":"2025-04-02","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Grade 3b Follicular Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Grade 3b Follicular Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory Transformed Non-Hodgkin Lymphoma"],"enrollment":38,"completionDate":"2028-12-31"},{"nctId":"NCT06563596","phase":"PHASE2","title":"Epco, Zanu, Ritux for R/R FL or MZL","status":"RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2025-01-21","conditions":["Follicular Lymphoma","Lymphoma","Non-Hodgkin Lymphoma","Relapsed Lymphoma","Refractory Lymphoma","Marginal Zone Lymphoma"],"enrollment":45,"completionDate":"2030-03-01"},{"nctId":"NCT06830759","phase":"","title":"Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-03-28","conditions":["Diffuse Large B-cell Lymphoma","Follicular Lymphoma"],"enrollment":700,"completionDate":"2031-09"},{"nctId":"NCT06723457","phase":"PHASE2","title":"Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2025-07-25","conditions":["Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder","Refractory B-Cell Non-Hodgkin Lymphoma"],"enrollment":34,"completionDate":"2029-02-18"},{"nctId":"NCT06676033","phase":"PHASE1","title":"Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2025-07-18","conditions":["Leukemia, Chronic Lymphocytic","Richter Syndrome"],"enrollment":5,"completionDate":"2027-07-01"},{"nctId":"NCT07082868","phase":"PHASE1","title":"A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-13","conditions":["Primary Central Nervous System Lymphoma (PCNSL)","Primary Central Nervous System Lymphoma","Relapsed Primary Central Nervous System Lymphoma","Refractory Primary Central Nervous System Lymphoma","Central Nervous System Lymphoma","Secondary Central Nervous System Lymphoma","Secondary Central Nervous System Lymphoma (SCNSL)"],"enrollment":26,"completionDate":"2028-08"},{"nctId":"NCT07393204","phase":"","title":"Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrés José Maria Ferreri","startDate":"2025-12-10","conditions":["Relapsed Diffuse Large B-cell Lymphoma (DLBCL)","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":150,"completionDate":"2026-12-10"},{"nctId":"NCT07365306","phase":"PHASE2","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-12-30","conditions":["Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":43,"completionDate":"2028-12-30"},{"nctId":"NCT06575686","phase":"PHASE2","title":"Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2025-03-11","conditions":["Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3a Follicular Lymphoma","Refractory Grade 1 Follicular Lymphoma","Refractory Grade 2 Follicular Lymphoma","Refractory Grade 3a Follicular Lymphoma"],"enrollment":33,"completionDate":"2028-07-16"},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":["B-Cell Non-Hodgkin Lymphoma","Burkitt Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-Cell Lymphoma","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce"],"enrollment":18,"completionDate":"2030-05-31"},{"nctId":"NCT05852717","phase":"PHASE2","title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Dipenkumar Modi","startDate":"2023-10-31","conditions":["Large Cell Lymphoma, Diffuse","Relapsed Cancer","Refractory Cancer"],"enrollment":32,"completionDate":"2028-11"},{"nctId":"NCT07108998","phase":"PHASE2","title":"Study of Epcoritamab as a Consolidation Therapy in CLL/SLL","status":"RECRUITING","sponsor":"Zulfa Omer","startDate":"2025-08-22","conditions":["CLL/SLL","CLL","SLL","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Small Lymphocytic Lymphoma Variant","Chronic Lymphocytic Leukemia Variants"],"enrollment":22,"completionDate":"2029-07-01"},{"nctId":"NCT05783609","phase":"PHASE2","title":"Epcoritamab and Rituximab for First-line Follicular Lymphoma","status":"RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-06-21","conditions":["Follicular Lymphoma","Low Grade Non-Hodgkin's Lymphoma, Adult"],"enrollment":100,"completionDate":"2030-02"},{"nctId":"NCT06112847","phase":"PHASE2","title":"Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2024-01-24","conditions":["Follicular Lymphoma"],"enrollment":29,"completionDate":"2026-07-17"},{"nctId":"NCT06796998","phase":"PHASE2","title":"Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"Izidore Lossos, MD","startDate":"2025-10-13","conditions":["Marginal Zone Lymphoma","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Splenic Marginal Zone Lymphoma","Nodal Marginal Zone Lymphoma"],"enrollment":25,"completionDate":"2031-04-15"},{"nctId":"NCT07197307","phase":"PHASE2","title":"Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"NOT_YET_RECRUITING","sponsor":"Universität Münster","startDate":"2025-10-15","conditions":["Aggressive Diffuse Large B-cell Lymphoma","High-grade B-cell Lymphoma (HGBL)","Follicular Lymphoma (FL) Grade 3B"],"enrollment":120,"completionDate":"2030-01-15"},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Nodal Marginal Zone Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":25,"completionDate":"2030-08-01"},{"nctId":"NCT06672705","phase":"PHASE1","title":"Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders","status":"RECRUITING","sponsor":"Timothy Voorhees","startDate":"2025-06-16","conditions":["Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder","EBV-Related Post-Transplant Lymphoproliferative Disorder","Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder","Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder","Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder","Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder"],"enrollment":26,"completionDate":"2026-12-31"},{"nctId":"NCT07126236","phase":"PHASE2","title":"Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2025-08-04","conditions":["Large B Cell Lymphoma"],"enrollment":80,"completionDate":"2031-12"},{"nctId":"NCT05409066","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-09-20","conditions":["Follicular Lymphoma (FL)"],"enrollment":549,"completionDate":"2029-12"},{"nctId":"NCT06414148","phase":"PHASE2","title":"MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2024-05-14","conditions":["Relapsed/Refractory Large B-cell Lymphoma"],"enrollment":40,"completionDate":"2028-05"},{"nctId":"NCT06447376","phase":"PHASE1","title":"Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab","status":"RECRUITING","sponsor":"Taylor Brooks","startDate":"2025-01-14","conditions":["Non-Hodgkin Lymphoma","Cytokine Release Syndrome"],"enrollment":20,"completionDate":"2028-09-01"},{"nctId":"NCT05206357","phase":"PHASE1","title":"Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-10-04","conditions":["Non-hodgkin Lymphoma"],"enrollment":17,"completionDate":"2028-11"},{"nctId":"NCT06458439","phase":"PHASE2","title":"Epcoritamab-CAR T Cells for Large B-cell Lymphomas","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2024-09-24","conditions":["Lymphoma, Non-Hodgkin","Relapsed Diffuse Large B Cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma","High-grade B-cell Lymphoma","Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":31,"completionDate":"2027-12"},{"nctId":"NCT05451810","phase":"PHASE2","title":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-08-17","conditions":["Diffuse Large B-Cell Lymphoma","Classic Follicular Lymphoma"],"enrollment":184,"completionDate":"2027-03"},{"nctId":"NCT05578976","phase":"PHASE3","title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-02-08","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":900,"completionDate":"2029-12"},{"nctId":"NCT05201248","phase":"PHASE1,PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":["B-Cell Non-Hodgkin Lymphoma"],"enrollment":49,"completionDate":"2025-04"},{"nctId":"NCT04358458","phase":"PHASE1,PHASE2","title":"First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas","status":"TERMINATED","sponsor":"Genmab","startDate":"2020-03-13","conditions":["Diffuse Large B-cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma","Mantle Cell Lymphoma","Chronic Lymphocytic Leukemia","High-grade B-cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma"],"enrollment":46,"completionDate":"2023-07-28"},{"nctId":"NCT06238648","phase":"PHASE2","title":"Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2024-01-31","conditions":["Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-Cell Lymphoma","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":120,"completionDate":"2030-12-31"},{"nctId":"NCT06287398","phase":"PHASE2","title":"Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL","status":"RECRUITING","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2023-12-11","conditions":["DLBCL - Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","DLBCL, Nos Genetic Subtypes","High Grade B-Cell Lymphoma, Not Otherwise Specified","Follicular Large Cell Lymphoma, Relapsed","Follicular Large Cell Lymphoma"],"enrollment":39,"completionDate":"2031-11"},{"nctId":"NCT05791409","phase":"PHASE1,PHASE2","title":"Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-04-10","conditions":["CLL/SLL"],"enrollment":112,"completionDate":"2032-11"},{"nctId":"NCT05848765","phase":"PHASE2","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-09-04","conditions":["Relapsed Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":284,"completionDate":"2031-11-30"},{"nctId":"NCT05733650","phase":"","title":"Expanded Access Program for Epcoritamab","status":"APPROVED_FOR_MARKETING","sponsor":"Genmab","startDate":"","conditions":["Large B-cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","High Grade B-cell Lymphoma (HGBCL)","Grade 3B Follicular Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT05692050","phase":"","title":"Expanded Access to Epcoritamab","status":"NO_LONGER_AVAILABLE","sponsor":"AbbVie","startDate":"","conditions":["Lymphoma"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03625037"],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"EPKINLY"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"SUBCUTANEOUS","productName":"EPKINLY"}]},"crossReferences":{"MMSL":"367260","NDDF":"019447","UNII":"D6OMY2L0WA","VANDF":"4042278","INN_ID":"11078","RXNORM":"2637392","UMLSCUI":"C5418281","chemblId":"CHEMBL4650393","ChEMBL_ID":"CHEMBL4650393","KEGG_DRUG":"D12368","DRUGBANK_ID":"DB16672","IUPHAR_LIGAND_ID":"11442"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Genmab US, Inc.","brandName":"EPKINLY","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"Genmab Us, Inc.","relationship":"Original Developer"}],"publicationCount":158,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Genmab Us, Inc.","recentPublications":[{"date":"2026 Mar 27","pmid":"41896935","title":"Cytokine release syndrome-compatible fever after initiation of local radiotherapy during late-phase epcoritamab therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report.","journal":"Journal of pharmaceutical health care and sciences"},{"date":"2026 Feb 19","pmid":"41881714","title":"Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6.","journal":"Clinical lymphoma, myeloma & leukemia"},{"date":"2026 Jan-Dec","pmid":"41867647","title":"Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report.","journal":"Case reports in oncology"},{"date":"2026 Feb","pmid":"41835636","title":"Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab.","journal":"Cureus"},{"date":"2026 Mar 12","pmid":"41813134","title":"Diffuse Large B-cell Lymphoma Complicated by Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity on Day 355 of Epcoritamab Therapy: A Case Report.","journal":"Journal of clinical and experimental hematopathology : JCEH"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Genmab Us, Inc.","companyId":"genmab-us-inc","modality":"Monoclonal antibody","firstApprovalDate":"2023","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-05-19T00:00:00.000Z","mah":"GENMAB US, INC.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-18T00:00:00.000Z","mah":"GENMAB US, INC.","brand_name_local":null,"application_number":"BLA761324"},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":"EMEA/H/C/005985"},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tepkinly","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":22,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:22:09.942762+00:00","fieldsConflicting":6,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}